 
Amendment 4 12/04/15   Page 1 of 60 
  
 
A Phase I/II Trial of Carfilzomib , Pegylated Liposomal Doxorubicin , and Dexamethasone  
for the Treatment of Relapsed /Refractor y Multiple Myeloma  
 
Washington University School of Medicine  
Division of Oncology  
660 South Euclid Avenue, Box 8007 
St. Louis, MO 63110  
 
HRPO #: 201102043  
IND #:  111755  
    ClinicalTrials.gov # [STUDY_ID_REMOVED]  
 
Principal Investigator:  Ravi Vij, M.D.  
    660 S. Euclid Avenue  
    Campus Box 8007  
    St Louis, MO 63110   
     Telephone: 314 -454-8323  
     Fax: 314 -454-7551  
     Email: rvij@dom.wustl.edu  
 
 Sub-Investigators:   Camille Abboud, MD   
John DiPersio, MD, PhD  
Timothy Graubert, MD  
Keith Stockerl -Goldstein, MD  
Michael Tomasson, MD   
Geoffrey Uy, MD  
Matthew Walter, MD  
Peter  Westervelt, MD, PhD  
 
Statistician :   Feng Gao , Ph.D.  
  
 Study Drugs:    Carfilzomib  
     Pegylated liposomal doxorubicin  (Doxil®  or Lipodox )  
     Dexamethasone   
 
Protocol Version Date:  Amendment 4 12/04/2015  
       
  
 
A Phase I/II Trial of Carfilzomib and Pegylated Liposomal Doxorubicin for the Treatment 
of Refractory/Relapsed Multiple Myeloma  
 

 
Amendment 4 12/04/15   Page 2 of 60 
 SCHEMA  
 
Carfilzomib will be administered on Days 1, 2, 8, 9, 15, and 16 during Cycles 1 through 6 , and 
on Days 1, 8, 15, and 22 beginning on Cycle 7 until disease progression  or clinical relapse . 
 
Pegylated liposomal doxorubicin (PLD) will be administered on Day 8 during Cycles 1 through 
6. 
 
Dexamethasone (Dex) will be administered on the same schedule as Carfilzomib  (for patients  in 
part 2  of phase 1  and phase 2 .)  
 
Phase I  
 
Part 1 - A maximum  of 24 participants  eligible for Maximal Tolerated Dose (MTD ) analysis will 
be enrolled t o determine th e MTD  of carfilzomib in combination with pegylated liposomal  
doxorubicin (PLD) in participants  with relapsed or refractory multiple myeloma . 
 
Dose Level  Carfilzomib (mg/m2) 
IV  PLD  (mg/m2) IV 
-2  20  20 
-1  20 on D1 and D2 * 
27 starting on D8  20 
0 (Start)  20 on D1 and D2 * 
27 starting on D8  30 
1 20 on D1 and D2 * 
36 starting on D8  30 
2 20 on D1 and D2 * 
45 starting on D8  30 
3 20 on D1 and D2 * 
56 starting on D8  30 
*- Please note that the D1 and D2 c arfilzomib dose of 20mg/ m2 will only occur during  Cycle 1. 
For all subsequent cycles, patients will receive the same dose of carfilzomib throughout at what 
is noted in this table to be the D8 dose.  
 
Part 2 - After the MTD of carfilzomib in combination with  PLD  has been determined, dose 
escalation will resume at the MTD of carfilzomib and PLD  with the addition of dexamethasone. 
A maximum  of 12 participants  eligible for Maximal Tolerated Dose (MTD) analysis will be 
enrolled .  
  Screening Screening 
•D-21 to D1 Cycle 1 through 6Cycle 1 through 6
•Carfilzomib and 
Dex on D1, 2, 8, 9, 
15, 16 
•PLD on D8Cycles 3 -6 Cycles 3 -6
•Carfilzomib and 
Dex on D1, 8, 15, 
22
•PLD on D8Cycles 7 and beyond 
until progressionCycles 7 and beyond 
until progression
•Carfilzomib and 
Dex on D1, 8, 15, 
22
 
Amendment 4 12/04/15   Page 3 of 60 
  
Dose Level  Carfilzomib (mg/m2) 
IV  PLD  (mg/m2) IV Dex (mg) IV or PO  
-1  1 dose level below  the 
MTD  1 dose level below  the 
MTD  20 
0 (Start)  MTD  MTD  20 
 
Phase II  
 
Seventeen  participants  will be treated at the MTD of carfilzomib in combination with PLD and 
dexamethasone  to evaluate the  efficacy and toxicity in participants  with relapsed or refractory 
multiple myeloma.  Participants treated in phase 1 at the MTD will be counted as part of the 
phase two accrual.  
  
 
  
 
Amendment 4 12/04/15   Page 4 of 60 
 A Phase I/II Trial of Carfilzomib and Liposomal Doxorubicin for the Treatment of 
Refractory/Relapsed Multiple Myeloma  
 
TABLE OF CONTENTS  
 
1.0 BACKGROUND AND RATIO NALE  ................................ ................................ ..............................  6 
1.1 MULTIPLE MYELOMA  ................................ ................................ ................................ ......................  6 
1.2 PROTEASOME INHIBITION AND BORTEZOMIB (VELCADE ®) ................................ ............................  7 
1.3 CARFILZOMIB  ................................ ................................ ................................ ................................ ... 8 
1.4 PEGYLATED LIPOSOMAL DOXORUBICIN (DOXIL ® OR LIPODOX ) ................................ ..................  15 
1.5 DEXAMETHASONE  ................................ ................................ ................................ ..........................  16 
1.6 RATIONALE  ................................ ................................ ................................ ................................ .... 16 
1.7 CORRELATIVE STUDIES BACKGROUND  ................................ ................................ .........................  17 
2.0 OBJECTIVES  ................................ ................................ ................................ ................................ .. 17 
2.1 PRIMARY OBJECTIVES  ................................ ................................ ................................ ....................  17 
2.2 SECONDARY OBJECTIVES ................................ ................................ ................................ ...............  17 
3.0 PARTICIPANT SELECTIO N ................................ ................................ ................................ ........  18 
3.1 INCLUSION CRITERIA  ................................ ................................ ................................ .....................  18 
3.2 EXCLUSION CRITERIA  ................................ ................................ ................................ ....................  19 
3.3 INCLUSION OF WOMEN AND MINORITIES  ................................ ................................ ......................  21 
4.0 REGISTRATION PROCEDU RES  ................................ ................................ ................................  21 
4.1 CONFIRMATION OF PATIENT ELIGIBILITY  ................................ ................................ ......................  21 
4.2 PATIENT REGISTRATION IN THE SITEMAN CANCER CENTER DATABASE  ................................ ...... 21 
4.3 ASSIGNMENT OF UPN  ................................ ................................ ................................ ....................  21 
5.0 TREATMENT PLAN  ................................ ................................ ................................ ......................  22 
5.1 OVERVIEW  ................................ ................................ ................................ ................................ ..... 22 
5.2 PHASE I................................ ................................ ................................ ................................ ...........  22 
5.3 PHASE II ................................ ................................ ................................ ................................ .........  23 
5.4 REQUIREMENTS TO START TREATMENT (CYCLE 1 DAY 1) ................................ ...........................  24 
5.5 ACCRUAL  ................................ ................................ ................................ ................................ ....... 24 
6.0 DOSE -LIMITING TOXICI TIES/DOSE MODIFICATI ONS  ................................ .....................  24 
6.1 DEFINITION OF DOSE-LIMITING TOXICITY  ................................ ................................ .....................  24 
6.2 DOSING MODIFICATIONS  ................................ ................................ ................................ ...............  25 
6.3 MISSED DOSES  ................................ ................................ ................................ ...............................  30 
6.4 CHANGES IN BODY SURFACE AREA (BSA)  ................................ ................................ ...................  30 
7.0 AGENT ADMINISTRATION  ................................ ................................ ................................ ........  30 
7.1 CARFILZOMIB  ................................ ................................ ................................ ................................ . 30 
7.2 PEGYLATED LIPOSOMAL DOXORUBICIN (DOXIL ® OR LIPODOX ) ................................ ..................  34 
7.3 DEXAMETHASONE  ................................ ................................ ................................ ..........................  36 
7.4 GENERAL CONCOMITANT MEDICATION AND SUPPORTIVE CARE GUIDELINES  .............................  37 
8.0 DURATION OF THERAPY  ................................ ................................ ................................ ...........  39 
8.1 CRITERIA FOR REMOVAL FROM STUDY  ................................ ................................ .........................  39 
8.2 DURATION OF FOLLOW -UP ................................ ................................ ................................ ............  39 
9.0 CRITERIA FOR RESPONS E ................................ ................................ ................................ ........  39 
9.1 COMPLETE RESPONSE  ................................ ................................ ................................ ....................  39 
9.2 STRINGENT COMPLETE RESPONSE  ................................ ................................ ................................ . 40 
9.3 NEAR-COMPLETE RESPONSE  ................................ ................................ ................................ .........  40 
9.4 VERY GOOD PARTIAL RESPONSE  ................................ ................................ ................................ ... 40 
9.5 PARTIAL RESPONSE  ................................ ................................ ................................ ........................  40 
9.6 MINIMAL RESPONSE  ................................ ................................ ................................ ......................  41 
 
Amendment 4 12/04/15   Page 5 of 60 
 9.7 STABLE DISEASE  ................................ ................................ ................................ ............................  41 
9.8 PROGRESSIVE DISEASE  ................................ ................................ ................................ ..................  41 
9.9 CLINICAL RELAPSE  ................................ ................................ ................................ ........................  42 
9.10 RELAPSE FROM COMPLETE RESPONSE  ................................ ................................ ......................  42 
10.0 STUDY CALENDAR  ................................ ................................ ................................ ..................  43 
11.0 DATA SUBMISSION SCHE DULE  ................................ ................................ ...........................  44 
12.0 CORRELATIVE STUDIES  ................................ ................................ ................................ ........  45 
13.0 SAFETY MONITORING, D ATA AUDITING, AND RE QUIRED REPORTING OF 
EVENT S ................................ ................................ ................................ ................................ ....................  46 
13.1 ADVERSE EVENTS  ................................ ................................ ................................ ......................  46 
13.2 UNANTICIPATED PROBLEMS  ................................ ................................ ................................ ...... 47 
13.3 NONCOMPLIANCE  ................................ ................................ ................................ ......................  47 
13.4 SERIOUS NONCOMPLIANCE  ................................ ................................ ................................ ....... 47 
13.5 PROTOCOL EXCEPTIONS  ................................ ................................ ................................ ............  47 
13.6 PREGNANCY  ................................ ................................ ................................ ...............................  48 
13.7 REPORTING TO THE HUMAN RESEARCH PROTECTION OFFICE (HRPO)  AND THE QUALITY 
ASSURANCE AND SAFETY MONITORING COMMITTEE (QASMC)  AT WASHINGTON UNIVERSITY  ........  48 
13.8 REPORTING TO THE FDA  ................................ ................................ ................................ ...........  48 
13.9 REPORTING TO  AMGEN  ................................ ................................ ................................ ............  49 
13.10  TIMEFRAME FOR REPORTING REQUIRED EVENTS  ................................ ................................ ..... 50 
14.0 DATA AND SAFETY MONI TORING PLAN  ................................ ................................ .........  50 
14.1 EXTERNAL DATA AUDITING  ................................ ................................ ................................ ...... 51 
15.0 ENDPOINTS  ................................ ................................ ................................ ................................  51 
15.1 PRIMARY OUTCOME ANALYSES  ................................ ................................ ................................  51 
15.2 SECONDARY OUTCOME ANALYSES  ................................ ................................ ...........................  51 
16.0 STATISTICAL ANALYSIS  ................................ ................................ ................................ ....... 52 
17.0 REFERENCES  ................................ ................................ ................................ .............................  53 
APPENDIX A: ECOG PER FORMANCE STATUS SCAL E ................................ ...............................  56 
APPENDIX B:  KARNOFS KY PERFORMANCE STATU S SCALE  ................................ ................  57 
APPENDIX C: COCKCROF T-GAULT FORMULA  ................................ ................................ ...........  58 
APPENDIX D: NCI COMM ON TERMINOLOGY CRITE RIA FOR ADVERSE EVEN TS 
VERSION 4.0  ................................ ................................ ................................ ................................ ............  59 
APPENDIX E: MEDWATCH  3500  ................................ ................................ ................................ ........  60 
  
 
Amendment 4 12/04/15   Page 6 of 60 
 1.0 BACKGROUND AND RATIONAL E 
 
1.1 Multiple Myeloma  
 
Multiple myeloma (MM) is a multifocal plasma cell neoplasm resulting from the clonal 
expansion of terminally differentiated B -cells.  The disease is characterized by a serum or 
urine monoclonal protein and skeletal destruction with osteolytic lesions, bone pain, 
pathologic fractures  and hypercalcemia. Recurrent infections from depressed normal 
immunoglobulin production, renal dysfunction from light chain production , and anemia 
from generalized marrow involvement are also common.  In the United States, MM is the 
second most common hem atologic malignancy behind non -Hodgkin’s lymphomas with 
an estimated 15,270 new cases and 11,070 deaths in 2004. [1]  
 
Progress in the management of MM has been modest since the introduction of melphalan 
more than 25 years ago. Melphalan combined with prednisone produces an objective 
response of 50 -60% although median survival remains approximately 3 years with 5 -10% 
of patients  surviving 10 or more years [2]. More aggressive chemotherapy regimens, 
though associated with higher response rates , have had little impact on improving 
survival  [3-8]. However, corticosteroids when used alone can induce a response in 
approximately 30% of patients , similar to rates seen with combination c hemotherapy in 
refractory patients [9, 10 ].   Interferon  (IFN -) in combination with chemotherapy is 
known to prolong the plateau phase of remission [11, 12] . The combination of IFN - and 
corticosteroids has been shown to be better than IFN - alone in improving progression 
free survival [13].  
 
High dose chemotherapy (HDCT) with autologous stem cell transplant (ASCT) has 
resulted in a higher rate of complete response  (CR)  (22% vs . 5%) and longer progression 
free survival (PFS) and overall survival (OS) (18-27 months and  37-60+ months, 
respectively) compared to standard dose chemotherapy  [14]. However , high dose 
chemotherapy with transplant is not curative and currently there is great interest in 
developing therapies that prolong the remission duration following autologous 
transplantation for MM.  
 
With the advent of novel targeted agents, the majority o f patients have experienced 
improved survival outcomes in recent years.  The immunodulatory agents thalidomide 
and lenalidomide and the proteasome inhibitor bortezomib are routinely used as first line 
therapy and have thus improved the outcomes for myeloma  patients .  However, despite 
the availability of these newer therapies, the overall prognosis of patients  with myeloma 
remains poor.  Furthermore, patient s who do respond and survive salvage chemotherapy 
will almost invariably relapse , underscoring the nee d for additional effective agents 
against myeloma.  
  
 
Amendment 4 12/04/15   Page 7 of 60 
  
1.2 Prote asome Inhibition and Bortezomib  (Velcade ®) 
 
1.2.1 The Proteasome  
 
The ubiquitin -proteasome pathway plays an essential role in cellular homeostasis. 
Eukaryotic cells target specific proteins for destruct ion by tagging them with 
ubiquitin. Polyubiquitinated proteins bind to the proteasome. The 26 S 
proteasome is an adenosine triphosphate -dependent multicatalytic protease which 
consists of a core 20S particle, which contains the catalytic proteinase functio n. 
This is symmetrically bound to 2 copies of a regulatory 19S particle, which 
recognizes the ubiquitinated substrates. The 26S proteasome performs a 
“housekeeping” role that acts to dispose of used up or damaged proteins and 
create antigenic peptides for presentation to immune effector cells.  
 
In addition, the ubiquitin -proteasome pathway plays an important role in 
regulating the cell cycle, neoplastic growth and metastases. [15, 16]   A number of 
key regulatory proteins are temporally degraded during the cell cycle by the 
ubiquitin -proteasome pathway. The orderly deg radation of these proteins is 
required for the cell to progress through the cell cycle and undergo mitosis. One 
of the targets is the tumor suppressor gene p53, which is required for the 
transcription of a number of genes involved in cell cycle progression  and also 
plays an important role in apoptosis.  Cyclins and cyclin -dependent kinase 
inhibitors p21 and p27 are other growth regulatory proteins degraded by the 
ubiquitin proteasome pathway.  
 
The ubiquitin -proteasome pathway is also required for transcript ional regulation. 
Nuclear factor kappa -B is a key transcription factor, whose activation is regulated 
by the proteasome -mediated degradation of the inhibitor protein I -kappa B. NF-
κB regulates the expression of adhesion molecules such as E -selectin, interc ellular 
adhesion molecule 1 (ICAM -1) and vascular adhesion molecule 1 (VCAM 1).  
These adhesion molecules in turn direct the adhesion and extravasation of tumor 
cells.  NF-κB is also required by a variety of cells to maintain cell viability due to 
the prod uction of anti -apoptotic proteins like bcl -2 or growth factors such as 
interleukin -6. 
 
1.2.2 Bortezomib  (Velcade®)  
 
Bortezomib is the first proteasome inhibitor developed to be used in routine 
clinical practice for myeloma treatment. It is a reversible inhibitor of the 
proteasome blocking signal transduction pathways mediated by NF -κB resulting 
in the stimulation of apo ptosis  by inhibiting the proteasome degradation of IκB.   It 
has been shown to be effective in the first line setting as well as in patient s with 
relapsed and refractory myeloma.   
 
In newly diagnosed elderly patient s, the phase III VISTA trial compared 
 
Amendment 4 12/04/15   Page 8 of 60 
 bortezomib plus melphalan plus prednisone versus melphalan plus prednisone and 
demonstrated a 52% reduction in the risk of disease progression and a median 
time to progression (TTP) of 24 months versus 16.6 months (P<0. 001).  After a 
median follow -up of 25.9 months, the 3 -year survival rates were also better with 
the bortezomib -containing regimen (72% vs. 59%, p -0.003). [17]   
 
In the relapsed/refractory population, the phase III APEX trial demonstrated the 
superiority of a bortezomib plus high dose dexamethasone versus high -dose 
dexamethasone alone.  The median TTP was longer (6.2 vs. 3.5 month s), 
p<0.001), more patient s experienced a >PR (38% vs. 18%; p<0.001) and CR (6% 
vs. <1%, p<0.001), and the overall 1 year survival was improved (80% vs. 66%; 
p=0.003). [18]  
 
1.3 Carfilzomib  
 
1.3.1 Overview of Carfilzomib  
 
Carfilzomib is a novel inhibitor of the p roteasome.  It is an irreversible 
tetrapeptide ketoepoxide -based inhibitor of the chymotrypsin -like activity of the 
20S proteasome, which is structurally and mechanistically different from the 
dipeptide boronic acid reversible proteasome inhibitor bortezom ib.  It is more 
selective for the chymotrypsin -like protease, having less inhibitory activity 
against the other two active subunits.  In addition, when measured against a broad 
panel of proteases including metallo, aspartyl, and serine proteases, carfilzom ib 
demonstrated less reactivity against non -proteasomal proteases when compared to 
bortezomib.   
 
1.3.2 Pre-clinical Studies of Carfilzomib  
 
Based upon in vitro  and in vivo  studies, it is anticipated that more intense and 
longer duration of proteasome inhibition can be achieved with carfilzomib relative 
to bortezomib, resulting in enhanced anti -tumor activity.  Continuous (72 -hour) 
exposure to carfilzomib was associated with  potent cytotoxic and pro -apoptotic 
activity across a broad panel of tumor -derived cell lines in culture  [19].  
Incubation of hemat ologic tumor cell lines with carfilzomib for as little as 1 hour 
led to rapid inhibition of proteasome activity followed by accumulation of 
polyubiquinated proteins and induction of apoptotic cell death.  Carfilzomib was 
also cytotoxic in bortezomib -resist ant tumor cell lines. [20] 
 
Preclinical studies in rats and monkeys have been performed administering 
carfilzomib intravenously (IV) for 5 consecutive days followed by 9 days of rest 
for 2 cycles.  Proteasome inhibition of more than 80% was achieved, suggesting 
that high -level inhibi tion of the proteasome with the epoxyketone class is 
possible, affording new opportunities to escalate dose to optimize anti -tumor 
effects.  This finding was in contrast to preclinical testing with the boronic class 
of inhibitors that prohibited uninterrup ted daily dosing due to lethal toxicity.   
 
Amendment 4 12/04/15   Page 9 of 60 
  
1.3.3 Non-Clinical Pharmacodynamics and Pharmacokinetics of 
Carfilzomib   
 
1.3.3.1     Pharmacodynamics  
 
The in vivo  pharm acodynamics ( PDn) and efficacy of carfilzomib have 
been evaluated using direct measurement of proteasome enzyme activity 
in a variety of tissues and determination of the antitumor response in mice 
bearing established subcutaneous tumors.  
 
The PDn of carfilzomib has been de termined by measurement of 
chymotrypsin -like proteasome activity in tissue extracts following IV 
bolus administration in rats. Dose -dependent proteasome inhibition was 
observed 1 hour after dose administration in all tissues examined, with the 
exception of  brain (Demo 2007). Proteasome activity recovered in 
nucleated tissues with a half -life of approximately 24 hours.  With a 12 
mg/m2 (2 mg/kg) dose (the STD 10 on a QDx5 schedule), proteasome 
inhibition exceeded 80% in multiple tissues (blood, adrenal, heart , lung, 
and bone marrow). Equivalent levels of proteasome inhibition were seen 
in blood and tissues when carfilzomib was delivered as a bolus 
administration or a 30 -minute infusion  indicating that the biodistribution 
and PDn of carfilzomib are a function o f the total dose administered and 
not the maximum plasma concentration (C max).  
 
1.3.3.2     Pharmacokinetics  
 
The pharmacokinetics ( PK) of carfilzomib was examined following IV 
bolus administration to Sprague -Dawley rats and cynomolgus monkeys. 
There was a dose -dependent increase in the area under the curve (AUC) 
and a biphasic distribution profile following administration. The terminal 
half-life (t 1/2) was calculated to be 5 to 17 minutes in rats and 7 minutes in 
monkeys. The plasma clearance of carfilzomib is 195 to 319  mL/min/kg in 
rats and 187 to 286  mL/min/kg in monkeys, which is higher than the liver 
blood flow for both species, indi cating that clearance occurred largely 
extrahepatically in these species.  
 
When carfilzomib was given as 30 -minute IV infusion at 8 mg/kg to rats, 
the concentration at steady state was approximately 28 -fold lower than the 
Cmax with IV bolus at the equival ent doses. Other PK parameters 
(clearance, AUC, and t 1/2) were comparable between bolus and infusion 
dosing. Similar PDn (proteasome inhibition in blood and tissues) between 
bolus and infusion dosing supported accessibility of carfilzomib to target 
tissues  using the 30 -minute infusion protocol.  
  
 
Amendment 4 12/04/15   Page 10 of 60 
  
1.3.3.3  Metabolism , Distribution , and Excretion  
 
1.3.3.3.1  Metabolism  
     
Carfilzomib is rapidly and extensively metabolized following IV 
administration to rats, monkeys, and humans. The predominant 
metabolites are carfilzomib diol as well as peptide fragments and 
amino acids derived from carfilzomib, with no unique metabolites 
identified in humans, suggesting that peptidase cleavage and 
epoxide hydrolysis are the principal pathways of metabolism in all 
these species . The metabolites do not inhibit proteasome activity. 
Cytochrome P450 -mediated pathways are not significant in the 
overall metabolism of carfilzomib.  
 
Carfilzomib is also rapidly metabolized by peptidases and epoxide 
hydrolases in vitro upon incubation wit h rat blood and tissue 
homogenates derived from the lung, kidney, and liver, further 
corroborating the extrahepatic mechanisms of metabolism in vivo . 
 
1.3.3.3.2  Distribution  
 
The V ss was 0.3 to 2.0 L/kg  and 0.3 to 1.1  L/kg, respectively, for 
rats and monkeys. Due to metabolism in a variety of tissues and 
the irreversible, covalent binding of carfilzomib to the 20S 
proteasome, the V ss values may underestimate the extent of tissue 
distribution of carfilzomib. Potent prot easome inhibitory effects in 
a variety of tissues following IV administration to rats at different 
dose levels and detection of radioactivity in a variety of tissues 
with an IV administration of [ 3H-Phe]-carfilzomib to rats at 2 
mg/kg (12 mg/m2) indicated rapid and wide distribution of 
carfilzomib to tissues except brain.  
 
An in vitro  protein -binding study using equilibrium dialysis 
demonstrated that approximately 9 7% of carfilzomib is bound to 
human plasma proteins, similar to rats and monkeys.  
 
1.3.3.3.3  Eliminatio n 
 
Excretion of [ 3H-Phe]-carfilzomib was determined by quantitative 
whole -body autoradiography in rats receiving a single IV bolus 
administration of 2 mg/kg (12 mg/m2). Urine and feces accounted 
for 14.1% and 18% of the dosed radioactivity, respectively, a t 168 
hours post -dose. Approximately 44% of the administered 
radioactivity remained in tissues, indicating slow elimination of 
drug-derived radioactivity, likely due to incorporation of 3H-
 
Amendment 4 12/04/15   Page 11 of 60 
 phenylalanine into cellular proteins.  
 
Excretion was also determined in bile duct -cannulated rats 
following a single IV bolus  administration of 2 mg/kg. Carfilzomib 
was excreted mainly in the form of metabolites,  with less than 1% 
of the dose excreted intact. About 57% of the dose was recovered  
within 24 hours of  dosing in both bile and urine samples. The 
limited recovery was likely  due to target binding in cells unable to 
synthesize new proteasomes (e.g., red blood  cells [RBCs]) and 
peptidic metabolites that cannot be differentiated from endogenous  
components.  
 
1.3.4 Clinical Pharmacokinetics, Metabolism, Distribution, and Excretion  
 
1.3.4.1   Pharmacokinetics  
 
Following IV administration of carfilzomib at ≥ 15 mg/m2 to patient s with 
hematological malignancies (PX -171-001 and PX -171-002), carfilzomib 
was rapidly cl eared from the systemic circulation with a half -life < 1 hour. 
The systemic clearance, which ranged from 2.7 to 30 L/minute, exceeded 
liver blood flow, suggesting that carfilzomib is largely cleared non -
hepatically.  
 
Assessment of the PK of carfilzomib in MM patient s with varying levels 
of renal dysfunction, including those on dialysis, is currently ongoing (PX -
171-005). As of the data transfer cutoff date of 10 July 2009, 16 patient s 
have been evaluated for PK and there has been no apparent effect of renal  
dysfunction on PK in preliminary analysis. Based on currently available 
data, carfilzomib can be administered to patient s with MM and substantial 
renal dysfunction without need for dose adjustment.  
 
Carfilzomib was also rapidly cleared in patient s with so lid tumors 
following IV administration (PX -171-007) with a half life of < 1 hour and 
systemic clearance exceeding hepatic blood flow. There was no systemic 
accumulation of carfilzomib after repeat doses. Both C max and AUC 
increased dose -proportionally from  20 to 36 mg/m2, indicating linear PK 
in the dose range tested.  
 
1.3.4.2  Metabolism  
 
Similar to the metabolic profile in rats and monkeys, the most abundant 
metabolites of carfilzomib in human plasma and urine collected from the 
patient s with hematological malignancies were peptide and amino acid 
fragments of carfilzomib and carfilzomib di ol, indicating that peptidase 
cleavage and epoxide hydrolysis are the principal pathways of metabolism 
of IV administered carfilzomib in humans. No significant oxidative 
 
Amendment 4 12/04/15   Page 12 of 60 
 metabolites mediated by cytochrome P450 enzymes were detected. None 
of these metabolit es have significant proteasome inhibition (or other 
known biological) activity.  
 
1.3.4.3  Distribution  
 
The V ss of carfilzomib ranged from 10 L to 228 L in patient s with 
hematological cancers. However, due to metabolism in tissues and 
irreversible binding of carfilzomib to the 20S proteasome, the V ss value 
may underestimate the actual tissue distribution of carfilzomib. The potent 
proteasome inhibitory effects in a v ariety of tissues in rats and broad 
distribution of the radioactivity in the quantitative whole body 
autoradiography study in rats following IV administration demonstrated 
wide tissue distribution of carfilzomib except brain. The  in vitro  binding 
of carfil zomib to human plasma proteins averaged 94% over the 
concentration range of 0.5 –5 μM.  
 
1.3.4.4  Excretion  
 
Carfilzomib is eliminated primarily in the form of inactive metabolites 
(mainly as peptide fragments). Renal excretion accounts for 20% –30% of 
the total dose and appears not to be affected by renal dysfunction (PX -
171-005).  
 
1.3.5 Current Clinical Experience with Carfilzomib  
 
1.3.5.1  Summaries of Phase I Studies  
 
Two Phase 1 studies have been completed; both evaluated carfilzomib in 
subjects with refractory or relapsed hematologic malignancy following at 
least 2 prior therapies. In the first study (Study PX -171-001, N = 29), the 
MTD was established at 15 mg/m2 as an IV bolus over 1 to 2 minutes. At 
the 20 mg/m2 dose, 2 of 5 subjects experienced DLTs of Grade 3 f ebrile 
neutropenia and chills (1 subject) and Grade 4 thrombocytopenia (1 
subject) during Cycle 1. In the second study (Study PX -171-002, N = 48), 
DLTs of renal failure, fatigue, and hypoxia were observed at different 
dose levels; no dose level (through 27  mg/m2) met the criteria for the 
MTD of carfilzomib. However, based on the safety information available, 
further dose escalation beyond 27 mg/m2 as an IV bolus over 2 minutes 
was not pursued. The expansion cohort received starting doses of 20 
mg/m2 in Cycl e 1 on Days 1, 2, 8, 9, 15, and 16, escalating up to 27 
mg/m2 in Cycle 2 as tolerated on Days 1, 2, 8, 9, 15, and 16.  
 
Three Phase 1 studies are ongoing. One study is being conducted in 
multiple myeloma subjects with end stage renal disease and another in 
subjects with relapsed advanced malignancies who have varying degrees 
 
Amendment 4 12/04/15   Page 13 of 60 
 of hepatic impairment, both testing the 56 mg/m2 dose (by Cycle 2 and 
beyond in subjects that tolerate the 20 and 27 mg/m2 doses) administered 
as a 30 -minute infusion. The third study is  evaluating once -weekly 
carfilzomib in combination with lenalidomide and dexamethasone in 
subjects with newly diagnosed or relapsed multiple myeloma.  
 
1.3.5.2  Phase 2 Experience with Carfilzomib as a monotherapy  
 
The initial Phase 1 studies administered carfilzomib as monotherapy on 5 
consecutive days with a 14 -day cycle; this resulted in sustained 
proteasome inhibition and a favorable safety profile [22].  Subsequent 
Phase 1 and 2 studies of carfilzomib monotherapy utili zed twice -weekly 
dosing for 3 weeks in a 28 -day cycle and have achieved higher tolerated 
doses with promising anti -tumor activity.  The most common adverse 
events have been non -hematologic, including fatigue, nausea, diarrhea, 
upper respiratory tract infec tion, and reversible elevations in creatinine.  
Severe peripheral neuropathies were rare: 2 cases of grade 3 in >200 
myeloma patient s treated, most with pre -existing neuropathy.  
Hematologic toxicities were seen, including anemia, transient 
thrombocytopeni a (cyclical, similar to bortezomib), and neutropenia with 
or without fever.  The level of grade 3 neutropenia is ~10% and appears to 
be lower than that observed with bortezomib.   
 
Two Phase 2 clinical studies are ongoing with carfilzomib in MM patient s, 
PX-171-003-A0 (N=46) in relapsed and refractory MM and PX -171-004 
(N=39)  in relapsed MM.  In both studies, patient s were dosed with 20 
mg/m2 on Days 1, 2, 8, 9, 15, and 16 on a 28 day schedule.  In these 
studies there were four cases of suspected or documen ted TLS prior to 
institution of the prophylaxis guidelines.  No further cases of TLS have 
been reported.  In both studies, the most common adverse events were 
fatigue, anemia, thrombocytopenia (primarily cyclical), gastrointestinal, 
and dyspnea.  Almost al l were Grades 1 or 2.  There were reported cases 
of increased in serum creatinine that were primarily <  Grade 2 and were 
transient, rapidly reversible, and non -cumulative.  A very low rate of 
treatment -emergent peripheral neuropathy, 2.2% Grade 3/4, was ob served 
in PX -171-003-A0 despite the fact that 78% of patient s had Grade 1/2 
neuropathy upon study entry [23].   
 
The response rate in PX -171-003-A0 was 18% PR, 7% MR and 41% SD 
in these patient s that entered the study with progressive disease and were 
refractory to their most recent therapy, often including bortezomib and/or 
an immunomodul atory drug (usually lenalidomide).  The median time to 
progression on the PX -171-003-A0 study was 5.1 months with a DOR of 
7.4 months (mean follow up of 7.6 months).  A “stepped up” dosing 
schedule, referred to as 20/27 mg/m2, has subsequently been incorporated 
into the PX -171-003 study (referred to as PX -171-003-A1) in order to 
 
Amendment 4 12/04/15   Page 14 of 60 
 maximize the clinical benefit of carfilzomib.  Patient s receive 20 mg/m2 
for the first cycle and 27 mg/m2 thereafter.  To date, this dosing schedule 
has been well tolerated.  An independent Safety Oversight Group (SOG) 
evaluated the safety data from the 40 of 250 patient s to be enrolled on the 
20/27 schedule and agreed that the trial should proceed without 
modification.  No cases of TLS were observed.  The most common 
adverse events were similar to the A0 portion of the study. A decrease in 
cases of renal impairment was observed from 47% all grades with 15% 
Grade 3/4 in A0 to 35% all grades and 2.2% Grade 3/4 in A1.  This is 
most likely due to the implem entation of guidelines for hydration.  
Treatment -emergent peripheral neuropathy remains low on this portion of 
the study with 15% Grade 1/2 and no Grade 3 or 4 reported to date on PX -
171-003-A1.  In addition, anemia rates in the PX -171-003-A1 (higher 
dose)  were lower than those reported in the PX -171-003–A0 portion of the 
study, possibly indicating that the higher dose of carfilzomib is achieving 
better clearing of neoplastic cells in the bone marrow.  Rates of 
thrombocytopenia and neutropenia were similar in the two cohorts, with 
Grade 3 neutropenia in ~5% without any Grade 4 neutropenia to date [23].   
As of May 2009, over 160 patient s with relapsed and refractory multiple 
myeloma have  received the 20/27 stepped -up dosing schedule in the PX -
171-003-A1 study.  Phase 1b/2 solid tumor study patient s are also 
receiving a stepped up dosing sche dule using 20/36 mg/m2. In this study, 
the stepped up dose is administered on Day 8 of Cycle 1 and for all 
subsequent doses.  As of April 2009, no MTD has been reached in this 
study and dose escalation to 45 mg/m2 is to be initiated.  
 
In PX -171-004, the su bset of patient s (N=14) that had not seen bortezomib 
had an ORR of 57% (7% CR, 14% VGPR and 36% PR), while the 
bortezomib treated patient s (N=17) had an ORR of 18% (18% PRs) [24].  
The median TTP was 11.1 and 8.3 months in these two groups, 
respectively.  Thus, carfilzomib can induce very high levels of response in 
patient s who have not previously been treated with bortezomib, and 
substantial anti -tumor activ ity is observed even in bortezomib -treated 
patient s.  Of note, disease control (PR + MR + SD) was achieved in ~65% 
of patient s with progressive MM entering the study.  Patient s on these 
studies have been treated for >12 cycles with good tolerability, and 
cumulative toxicity (e.g., bone marrow, severe fatigue, or neuropathy) 
have not been observed.  
 
Based on the results of these  trials, in July 2012 carfilzomib  received FDA 
approval for patients  who had relapsed/refractory multiple myeloma who 
have received at least two prior therapies, including bortezomib and an 
immunomodulatory agent, and have demonstrated disease progression on 
or within 60 days of the completion of the last therapy.[40]  
  
  
 
Amendment 4 12/04/15   Page 15 of 60 
  
1.4 Pegylated Liposomal Doxorubicin (Doxil®  or Lipodox ) 
 
Pegylated liposomal doxorubicin (PLD) was first compared with conventional 
doxorubicin in a randomized, phase III multicenter trial of metastatic breast cancer 
(MBC).  Two hundred ninety -seven patient s with MBC and no prior chemotherapy for 
metastatic dise ase were randomized to receive either 60 mg/m2 of PLD or conventional 
doxorubicin, in combination with 600 mg/m2 of cyclophosphamide, every 3 we eks until 
disease progression or unacceptable toxicity.  The study showed an improved toxicity 
panel compared to  doxorubicin with significantly reduced cardiotoxicity and less grade 4 
neutropenia, while providing comparable antitumor efficacy. [25]  This was confirmed in 
subsequent trials as O’ Brien and colleagues compared the use of PLD at a dose o f 50 
mg/m2 (every 4 weeks ) to doxorubicin 60 mg/m2 (every 3 weeks).  Cardiac event rates 
were based on reductions in left ventricular ejection fraction as a function of cumulative 
anthracycline dose.  This study demonstrated that in first -line treatment of  women with 
MBC, the efficacy of [progression -free survival (PFS)] of PLD is non -inferior to 
doxorubicin with significantly less cardiotox icity, myelosuppression, nausea , and 
vomiting. [26] 
 
Multicenter randomized phase  III trials in multiple myeloma showed that PLD -containing 
chemotherapy regimens (DVD – PLD (Doxil), vincristine (Oncovin) , dexamethasone) 
compared to a similar doxorubicin -containing regimen (VAD – vincristine  (Oncovin ), 
doxorubicin ( Adriamycin), dexameth asone) provided similar responses and survival, but 
that the DVD regimen was associated with significantly less toxicity and supportive 
care. [27,28]   PLD was associated with significantly less grade 3/4 neutropenia or 
neutropenic fever (10% vs. 24%; p=0.01), less antibiotic use, lower incidence of sepsis, 
decreased need for central venous access (p<0.0001) and growth factor support (p=0.03) 
and less alopecia compared to the doxorubicin regimen. [27]  A similar decreased toxicity 
and equivalent  tumor response was seen in phase II trials incorporating PLD for 
doxorubicin in the CHOP regimen for older patient s with aggressive (stage III/IV) NHL, 
in low -grade NHL and in previously untreated aggressive diffuse large B cell 
lymphoma [28-31] 
 
In a Phase III international study comparing the efficacy and safety of a combina tion of 
pegylated liposomal doxorubicin (PLD) plus bortezomib with bortezomib monotherapy 
in patient s with relapsed or refractory multiple myeloma, 646 patient s were randomly 
assigned to receive either intravenous bortezomib 1.3 mg/m2 on Days 1, 4, 8, and 11 of 
an every 21 -days cycle, or the same bortezomib regimen with PLD 30 mg/m2 on Day 4.  
Median time to progression was increased from 6.5 months for bortezomi b alone to 9.3 
months with the PLD + bortezomib combination (P = 0.000004; hazard ratio, 1.82 
[monotherapy v combination therapy]; 95% CI, 1.41 to 2.35).  The 15 month survival rate 
for PLD + bortezomib was 76% compared with 65% for bortezomib alone (P=0.0 3).  The 
complete plus partial response rate was 41% for bortezomib and 44% for PLD + 
Bortezomib, a difference that was not statistically significant.  Median duration of 
response was increased from 7 to 10.2 months (P=0.0008) with PLD + bortezomib.  
 
Amendment 4 12/04/15   Page 16 of 60 
 Grade  3 and 4 adverse events were more frequent in the combination group (80% vs. 
64%), with safety profiles consistent with the known toxicities of the two agents.   
 
Based on the results of this trial the combination of bortezomib and liposomal 
doxorubicin (Doxil) received FDA approval for patient s who had relapsed/refractory 
multiple myeloma who had failed at least one line of therapy and had not received prior 
bortezomib therapy. [17]  
 
In response to a critical shortage of (Doxil ), the FDA approved temporary importation of 
a replacement drug Lipodox (doxorubicin hydrochloride liposome injection) in Febuary 
2012. Lipodox has not bee n approved by the FDA, and therefore, cannot be considered a 
“generic” of Doxil but has the same active ingredient, dosage, strength, and route of 
administration. Lipodox is manufactured in a facility that has been inspected by the FDA 
and found to be in co mpliance with current good manufacturing practices.  
 
1.5 Dexamethasone  
 
There is increasing data on the superiority of three -drug regimens in the treatment of 
relapsed and refractory multiple myeloma.  Dexamethasone is commonly incorporated in 
these three -drug regimens because of its ability to improve response rates and duration of 
response without adding toxicity.   
 
The combination of bortezomib, PLD, and dexamethasone (VDD) has been shown to be 
efficacious and well tolerated. The overall response and duration of response of VDD 
exceeds that of the two drug regimens bortezomib -PLD, and bortezomib -dexamethasone 
suggesting a synergistic effect .[42]  
 
Dexamethasone has been added to carfilzomib, with and without additional agents, in 
many ongoing clinical trials. These clinical trials have indicated that adding 
dexamethasone may increase efficacy and tolerability of carfilzomib containing 
regimens. Many clinical trials that have incorporated dexamethasone into carfilzomib 
regimens have exceeded the  MTD of the single -agent carfilzomib studies.    
 
1.6 Rationale  
 
Based on the further need to improve the therapeutic interventions for multiple myeloma, 
the previous experience with proteasome inhibition, the potentially improved efficacy of 
carfilzomib over b ortezomib, and the success of bortezomib combination with PLD, the 
natural next step is to combine carfilzomib with PLD.  Furthermore, proteasome 
inhibitors have the ability to enhance the chemosensitivity in both in vitro  and in vivo  
preclinical models. [32]  Mechanistic studies have indicated that this effect is at least in 
part due to the inhibition of NF-κB, since many chemother apeutics activate NF-κB, 
which can lead to the induction of anti -apoptotic survival proteins such as members of the 
Bcl-2 family [33].  Several models utilizing anthracyclines in combination with a 
proteasome inhibitor have shown enhanced anti -tumor activity, including solid tumor 
models as well as multiple myeloma.  Our aim would be to first determine the maximal 
 
Amendment 4 12/04/15   Page 17 of 60 
 tolerated dose of the combination in participants  with relapsed/refractory myeloma and 
then to establish the efficacy of this novel combination [34, 35] .  
 
1.7 Correlative Studies Background  
 
The correlative studies  will focus on two areas : 
(1) evaluation of markers of response  
(2) evaluation of effects of carfilzomib , PLD, and dexamethasone on clonogenic 
myeloma cells  
 
In order to do so , we will collect bone marrow, peripheral blood, and plasma samples 
prior to treatment , at time of response, and/or at end of study . The first objective is to 
determine tumor characteristics that predict at least very good partial response (VGPR). 
VGPR has been associated with longer progression survival and overall survival . The 
second objective is to investigate the effects of carfilzomib and PLD on clonogenic 
myeloma cells. It is hypothesized t hat inability to cure the disease is related to the 
inability of eradicating chemoresistant clonogenic myeloma cells or myeloma stem cells. 
The effect of carfilzomib and its combinations on these cells is not known.  
 
 
2.0 OBJECTIVES  
 
2.1 Primary  Objectives  
  
• Phas e 1: Part 1 - To determine the Maximal Tolerated Dose (MTD) of carfilzomib in 
combination with pegylated liposomal doxorubicin (PLD) , in participants  with 
relapsed or refractory multiple myeloma.  Part 2 - To determine the Maximal 
Tolerated Dose (MTD) of carf ilzomib in combination with PLD and dexamethasone, 
in participants  with relapsed or refractory multiple myeloma.  
• Phase 2: To evaluate the efficacy and toxicity of carfilzomib in combination with 
PLD and dexamethasone in participants  with relapsed or refractory multiple 
myeloma.   
 
2.2 Secondary  Objectives  
  
• To evaluate the safety of carfilzomib in combination with PLD  and dexamethasone  in 
participants  with relapsed or refractory multiple myeloma.   
• To evaluate the effect of dexamethasone co -administration on the MTD of 
carfilzomib and PLD    
• To evaluate time  to tumor  progression, progression -free survival, and overall survival 
in this population treate d with carfilzomib in combination with PLD  and 
dexamethasone . 
 
  
 
Amendment 4 12/04/15   Page 18 of 60 
  
3.0 PARTICIPANT  SELECTION  
 
3.1 Inclusion Criteria  
 
A participant  must meet all of th e following criteria to be eligible for enrollment.  
 
3.1.1 Histologically confirmed diagnosis of multiple myeloma with a 
measurable  disease parameter  at time of screening . A measurable disease 
parameter is defined as  one or more of the following : 
• Serum monoclonal protein > 0.5 g/ dl. 
• 24 hour urine monoclonal protein  > 0.2 g/24 h our  
• Serum free light chain ratio >  5x normal ratio with an absolute 
difference of 10mg/dl between the involved and uninvolved free light 
chain . 
• Soft tissue plasmacytoma > 2 cm measurable by either physical 
examination and/or  applicable radiographs ( e.g. MRI,  CT, etc) .   
• Bone Marrow Plasma Cells  >30%. 
  
3.1.2 Documentation of at least one line of prior myeloma therapy  now with 
relapsed or refractory disease requiring re -treatment .   
 
3.1.3 > 18 years of age at time of signing the informed consent.  
 
Note:  No dosing or adverse event data are currently available on the use of 
carfilzomib in combination with PLD in participants  < 18 years of age. 
Thus,  children  and adolescents  are excluded from this study but will be 
eligible for future pediatric phase 2 combin ation trials.  
 
3.1.4 Performance status of ECOG < 2 or Karnofsky > 60 % (see Appendix A 
and B ). 
 
Note:  Participants  with lower performance status based solely on bone 
pain secondary to multiple myeloma will be eligible.  
 
3.1.5 Required Laboratory Values  
• ALT (SGPT) and AST (SGOT) < 2.5 x the upper limit of the 
institutional normal value (ULN).  
• Total bilirubin < 1.5 x ULN . 
• ANC > 1,000.  
• Hemoglobin > 8 g/dl . 
• Platelets > 50,000 . 
• Creatinine clearance > 15 ml/minute  using Cockcroft -Gault formula  
(See Appendix C) . 
• For those participants  receiving warfarin (Coumadin), unfractionated 
heparin, or low -molecular weight heparin therapy, the applicable 
 
Amendment 4 12/04/15   Page 19 of 60 
 coagulation parameter that is being monitored must be within the 
accepted therapeutic ranges for those indications .  
 
Note: Transfusions  and/or growth factor dependent participants  are not 
excluded if the above parameters can be achieved with such support.  
 
3.1.6 Females of childbearing potential (FCBP)  must agree to refrain from 
becoming pregnant while on study drug and for 3 months after 
discontinuation from study drug , and must agree to use adequate 
contraception including hormonal contraception, (i.e. birth control pills, 
etc), barrier method contrac eption (i.e. condoms), or abstinence  during 
that time frame .   
 
FCBP must agree to regular pregnancy testing during this timeframe (see 
section 10.1). Inclusion of FCBP requires two  negative pregnancy test s 
prior to enrollment . 
 
Note: all women, regardless  of age, should be considered FCBP unless 
they are surgically sterile (post hysterectomy, post bilateral oophorectomy, 
etc) or have been naturally post menopausal for > 24 consecutive months.  
 
3.1.7 Men engaging in sexual intercourse with a FCBP must agree to u se 
adequate contraception including hormonal contraception, (i.e. birth 
control pills, etc), barrier method contraception (i.e. condoms), or 
abstinence  while on study drug and for 3 months after discontinuation 
from study drug  
 
3.1.8 Ability  to understand and willing to sign a written informed consent 
document.  
 
3.2 Exclusion Criteria  
 
A participant  must not meet any of the following criteria to be eligible for enrollment.  
 
3.2.1 POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, 
monoclonal prot ein, and skin changes) . 
 
3.2.2 Plasma Cell Leukemia . 
 
3.2.3 Waldenstrom’s macroglobulinemia . 
 
3.2.4 Pregnant or lactating females . 
 
3.2.5 Use of any anti -myeloma drug therapy within 14 days of initiation of 
study drug treatment excluding corticosteroids if given for an indication 
other than myeloma.  
 
Amendment 4 12/04/15   Page 20 of 60 
  
Note:  Bisphosphonates are not considered anti -myeloma  drugs.    
 
3.2.6 Participation in an investi gational therapeutic study within 14 days of 
initiation of study drug treatment . 
 
3.2.7 Radiotherapy to multiple sites or immunotherapy within 14 days of 
initiation of study drug treatment  (localized radiotherapy to a single site at 
least 7 days before start is permissible).  
 
3.2.8 Major surgery within 14 days  of initiation of study drug treatment . 
 
3.2.9 Participants  in whom the required program of PO and IV fluid hydration is 
contraindicated . 
 
3.2.10  Prior history of a hypersensitivity reaction to PLD , doxorubicin , 
bortezomib , carfilzomib , or liposomal drug formulations other than PLD .  
 
History of reactions to liposomal drug formulations other than PLD should  
be evaluated individually and if their reactions were felt to have been due 
to the  encapsulated agent,  rather than the liposomal component itself  they 
should  be excluded at the discretion of the investigators.  
 
3.2.11  Participants  who are known to have active hepatitis A, B, or C viral 
infection may not participate in this study.  Active disease is defined as 
participants  with a known viral hepatitis whose liver func tion tests are 
elevated beyond the criteria indicated in Section 3.1.5. 
 
3.2.12  Known HIV-seropositive and are taking anti -retrovirals may not 
participate in this study because of potential interactions between these 
medications and the investigational agent. Participants  who are HIV -
seropositive and not on anti -retroviral ther apy and who otherwise meet the 
inclusion/exclusion  criteria will be eligible for the study.  
 
3.2.13  Compromised  cardiovascular function  defined as  any of the following : 
• EKG evidence of acute ischem ia. 
• EKG evidence of medically significant conduction system 
abnormalities . 
• History of myocardial infarction within the last 6 months . 
• Unstable angina pectoris or cardiac arrhythmia.  
• History of Class 3 or Class 4 New York Heart Association Congestive 
Heart Failure  
• Left ventricular ejection fraction (LVEF) < 55% by either 
echocardiography or radionuclide -based multiple gated acquisition 
(Echo  or MUGA) . 
 
Amendment 4 12/04/15   Page 21 of 60 
 3.2.14  Uncontrolled concurrent illness including : other hematologic or non -
hematologic malignancy,  active infection , or uncontrolled diabetes  
 
3.2.15  Any significant psychological, medical, or surgical condition thought to 
compromise the participant , the study, or prevent informed consent.   
 
3.3 Inclusio n of Women and Minorities  
 
Both men and women and members of all races and ethnic groups are eligible for this 
trial.  
  
 
4.0 REGISTRATION PROCEDURES  
 
Patients must not start any protocol intervention prior to registration through the Siteman 
Cancer Center.  
 
The following steps must be taken before registering patients to this study:  
 
1. Confirmation of patient eligibility  
2. Registration of patient in the Siteman Cancer Center database  
3. Assignment of unique patient number (UPN)  
 
4.1 Confirmation of Patient Eligibility  
 
Confirm patient eligibility by collecting the information listed below : 
 
1. Registering MD’s name  
2. Patient’s race, sex, and DOB  
3. Three letters (or two letters and a dash) for the patient’s initials  
4. Copy of signed consent form  
5. Completed eligibility checklist, signed and dated by a member of the study team  
6. Copy of appropriate source documentation confirming patient eligibility  
 
4.2 Patient Registration in the Siteman Cancer Center Database  
 
All patients  must be registered through the  Siteman Cancer Center database.  
 
4.3 Assignment of UPN  
 
Each patient will be identified with a unique patient number (UPN) for this study.  
Patients will also be identified by first, middle, and last initials.  If the patient has no 
middle initial, a dash wil l be used on the case report forms (CRFs).  All data will be 
recorded with this identification number on the appropriate CRFs.  
 
 
 
Amendment 4 12/04/15   Page 22 of 60 
 5.0 TREATMENT PLAN  
 
5.1 Overview  
 
Carfilzomib will be administered on Days 1, 2, 8, 9, 15, and 16 during Cycles 1 through 
6, and on Days 1, 8, 15, and 22 beginning on Cycle 7 until disease progression  or clinical 
relapse . Participants treated prior to approval of amendment 1 , will have c arfilzomib 
administered on Days 1, 2, 8, 9, 15, and 16 during Cycles 1 and 2 and on Days 1, 8, 15, 
and 22 beginning on Cycle 3.  PLD will be administered on Day 8 during Cycles 1 
through 6.  Dexamethasone will be administered on the same schedule as carfilzomib  
(patients treated in part 2 of phase 1 or phase 2) . 
  
Participants  that have PLD or dexamethasone discontinued for toxicity may remain on 
study to receive the planned study drug doses at the PI’s discretion.  
 
5.2 Phase I 
 
Part 1 - A phase I dose escalation of carfilzomib and PLD  will be performed using a 
standard 3 + 3 design with a maximum of 4 dose levels (24 participants ). The carfilzomib 
dose will be determined using a modified Fibonacci dose escalation, with a goal of three 
participants  at each dose level.   
 
Dose Level  Carfilzomib (mg/m2) 
IV  PLD  (mg/m2) IV 
-2  20  20 
-1  20 on D1 and D2 * 
27 starting on D8  20 
0 (Start)  20 on D1 and D2* 
27 starting on D8  30 
1 20 on D1 and D2 * 
36 starting on D8  30 
2 20 on D1 and D2 * 
45 starting on D8  30 
3 20 on D1 and D2 * 
56 starting on D8  30 
*- Please note that the D1 and D2 carfilzomib dose of 20mg/ m2 will only occur during 
Cycle 1. For all subsequent cycles, patients will receive the same dose of carfilzomib 
throughout at what is noted in this table to be the D8 dose.  
 
Part 2 - After the MTD of carfilzomib in combination with PLD has been determined, 
dose escalation will resume at the MTD of carfilzomib and PLD with the addition of 
dexamethasone. A maximum  of 12 participants  eligible for Maximal Tolerated Dose 
(MTD) analysis will be enrolled .  
  
 
Amendment 4 12/04/15   Page 23 of 60 
  
Dose Level  Carfilzomib (mg/m2) 
IV  PLD  (mg/m2) IV Dex (mg) IV or PO  
-1  1 dose level below the 
MTD  1 dose level below the 
MTD  20 
0 (Start)  MTD  MTD  20 
 
5.2.1  Dose Escalation Rule  
 
 
 
 
Only after the last participant  on at each dose level completes one cycle of 
treatment will the first participant  in the next dose level be enrolled.  
 
5.2.2 Definition of Maximum Tolerated Dose  
 
The maximum tolerated dose (MTD) is defined as the dose level immediately 
below the dose level at which 2 participants  of a cohort  (of 2 to 6 participants ) 
experience dose limiting toxicity (DLT) during the first cycle of treatment.  (See 
Section 6.0 for information on what constitutes a DLT.)  Dose escalation will 
proceed until the MTD has been reached.  
  
5.3 Phase II 
 
Having established an MTD in phase I, phase II will be conducted to assess  the efficacy 
and toxicity of carfilzomib in combination with PLD and dexamethasone in participants  
with relapsed or refractory multiple myeloma .  
 
Seventeen participants will be treated at the MTD of carfilzomib in combination with 
PLD and dexamethasone . Participants treated in phase 1 at the MTD will be counted as 
part of the phase two accrual. If < 5 successes (CR,  VGPR, or PR) are observed, we will Number of Participants  
with a DLT at a Dose Level  Escalation Decision Rule  
0 Enter 3 participants  at the next dose level.  
1 out of 3  Enter 3 more participants  at this dose level.  
 
If none of the additional participants  
experiences a DLT, then proceed to the next 
dose level.  If > 1 of the additional 
participants  experiences a DLT, then dose 
escalation is stopped and the level below is 
declared the MTD.  
> 2 Dose escalation is stopped.  Enter 3 more 
participants  at the next lower dose level if 
only 3 participants  had previously been 
treated at that dose level.  
 
Amendment 4 12/04/15   Page 24 of 60 
 consider this regimen ineffective in this participant  population and will not recommend 
further testing.  
 
5.4 Requirements to Start Treatment (Cycle 1 Day 1)  
 
• ALT (SGPT) and AST (SGOT) < 2.5 x the upper limit of the institutional normal 
value (ULN).  
• Total bilirubin < 1.5 x ULN.  
• ANC > 0.5. 
• Platelets > 25,000. 
• Creatinine clearance > 15 ml/min  using Cockcroft -Gault formula ( See Appendix C) . 
 
5.5 Accrual  
 
The anticipated  accrual rate for the phase I portion is 1 participant  per calendar month, 
with a total accrual time of two years. The anticipated accrual rate for the phase II portion 
is 1-2 participants  per calendar month, with a total accrual time of one year.  
 
 
6.0 DOS E-LIMITING TOXICIT IES/DOSE MODIFICATIONS  
 
6.1 Definition of Dose -limiting Toxicity  
 
Participants  will be evaluated for toxicity according to the Common Terminology Criteria 
for Adverse Events (CTCAE) of the National Cancer Institute (NCI) version 4.0.  A DLT 
is defined as any of the below treatment emergent toxicities with attribution to one or 
both of the study drugs that occur during Cycle 1.   Toxicities that occur in subsequent 
cycles will be handled through dose modifications ( Section 6.2) but will not be 
considered DLTs or figure into the definition of MTD.   
 
As the study uses a lead in do se of 20mg/m2 of Carfilzomib for days 1 and 2 for all dose 
levels, toxicity that requires dose reduction or doses to be held prior to Day 8 of cycle 1 
will not be considered a DLT, but  will result in the participant being ineligible for MTD 
analysis. The p articipant may remain on protocol therapy at the PI’s discretion, and an 
additional participant will be enrolled into the cohort for MTD analysis.  
 
In Phase 1 , inability to receive  >80% of Carfilzomib doses and 100% of PLD doses in 
Cycle 1 for reasons oth er than toxicity will result in the participant  being ineligible for 
MTD analysis. The participant  may remain on protocol therapy at the PI’s discretion, and 
an additional participant  will be enrolled into the cohort  for MTD  analysis .  
 
Inability to receiv e >80% of Dex doses  for reasons other than toxicity will result in the 
participant being ineligible for MTD analysis  (only patients treated in part 2) . 
 
Hematologic  DLTs  
• > Grade 4 t hrombocytopenia  
 
Amendment 4 12/04/15   Page 25 of 60 
 • > Grade 4 n eutropenia  
• > Grade 3 febrile neutropenia (f ever > 38.5 degrees C and ANC <1000k/cumm)  
 
Non-Hematologic  DLTs  
• ≥ Grade 2 neuropathy with pain  
• ≥ Any grade 3 non-hematologic toxicity (excluding nausea, vomiting, diarrhea)  
• ≥ Grade 3 nausea, vomiting, or diarrhea for > 3 days despite maximal 
antiemetic/antidiarrheal therapy  
• Any non -hematologic toxicity requiring a dose reduction within Cycle 1  
• Inability to receive Day 1 dose of Cycle 2 due to drug -related toxicity persisting 
from Cycle 1 or drug -related toxicity newly enco untered on Day 1 of Cycle 2  
• Delay of > 14 days in initiating Day 1 of Cycle 2  due to drug -related toxicity  
 
6.2 Dosing Modifications  
 
6.2.1 Overview   
 
Dose modifications  for hematologic and non-hematologic toxicities are 
summarized in sections 6.2.2 and 6.2.3 respectively. Participants who have 
treatment delayed for greater than four weeks  should discontinue protocol 
therapy.   
 
A maximum of 2 dose reductions of carfilzomib or Dex and 1 dose reduction of 
PLD will be allowed for each participant . More than two dose reductions of Dex 
or one dose reduction of PLD will require the agent be discontinued. Participants  
that permanently discontinue Dex or PLD due to toxicity can remain on study and 
receive the other planned study drug  doses at the investigator’ s discretion.  
Participants  requiring a third dose reduction of carfilzomib will have treatment 
discontinued.  
 
If the participant  tolerates the reduced dose for one cycle, the participant  may be 
dose escalated to the  study drug  dose(s) prior to reduction at the  discretion of the 
Investigator.  
 
Dose modifications should be followed directly for Cycle 1 for all patients treated 
in the phase I portion of the study. In Cycles 2+  for patients treated in the phase I 
portion, and for any cycle for patients treated in t he phase II portion, dose 
modifications and delays different from those stated in the protocol for 
management of toxicities will be permitted at the discretion of the  Principal  
Investigator.  
 
6.2.2 Dosing Modifications for Hematologic Toxicities  
 
6.2.2.1  Thrombocytopenia  
 
Only thrombocytopenia determined to be related to one or both study 
 
Amendment 4 12/04/15   Page 26 of 60 
 drugs require dose reductions or adjustment s as described in this section. 
Platelet transfusion support is permissible at the discretion of the treating 
physician.  Partic ipants  who have treatment delayed for greater than four 
weeks  should discontinue protocol therapy.   
 
Dose modifications for thrombocytopenia should be instituted as follows:  
 
Grade  Platelet             Modification  
4 < 25,000  First episode:  Hold therapy until platelets resolve 
to grade < 1 or baseline , then reduce carfilzomib by 
one dose level  
   Second episode:  Hold therapy until platelets 
resolve to grade < 1 or baseline , then further reduce 
carfilzomib by one more dose level and reduce PLD 
by one dose level  
    Third episode: Discontinue protocol therapy.  
 
6.2.2.2  Neutropenia  
 
Only neutropenia determined to be related to one or both study drugs 
require dose reductions or adjustments as described in this section.  
Colony -stimulating factor support  (such as G -CSF or GM -CSF) for 
neutropenia  is permissible at the discret ion of the treating physician , but 
should not be given prophylactical ly. Participants  who have treatment 
delayed for greater than four weeks  should dis continue protocol therapy.  
 
Dose modifications for neutropenia  should be instituted as follows:  
 
 
 
 
 
 
 
 
 
 
6.2.2.3  F
ebrile Neutropenia  (Fever  > 38.5 degrees Celsius  and ANC <  
1000 ) 
 
Colony -stimulating factor support (such as G -CSF or GM -CSF) for 
neutropenia  is permissible at the discret ion of the treating physician,  but 
should not be given prophylactically. Participants  who have treatment 
delayed for greater than four weeks should discontinue protocol therapy.   
  Grade  ANC             Modification  
4 < 500  First episode:  Hold therapy until ANC resolves to 
grade < 1 or baseline , then reduce carfilzomib by one 
dose level  
   Second episode:  Hold therapy until ANC resolves to 
grade < 1 or baseline , then further reduce carfilzomib 
by one more dose level and reduce PLD by one dose 
level  
    Third episode: Discontinue protocol therapy.  
 
Amendment 4 12/04/15   Page 27 of 60 
  
Dose modifications for febrile neutropenia  should be instituted as follows:  
 
Grade               Modification  
> 3  First episode:  Hold therapy until participant  recovers, 
then reduce carfilzomib by one dose level  
   Second episode:  Hold therapy until participant  
recovers, then further reduce carfilzomib by one more 
dose level and reduce PLD by one dose level  
    Third episode: Discontinue protocol therapy.  
 
6.2.3 Dosing Modifications for Non -Hematologic Toxicities  
 
Dose modification  guidelines for treatment related non-hematologic toxicities are 
as follows:  
 
Toxicity  Grade             Modification  
Allergic 
reaction/hypersensitivity  2 or 3  First episode:  Hold suspected drug(s) 
until ≤ grade 1, resume treatment at full 
dose.  
    Second episode:  Discontinue 
suspected drug(s).  
Allergic 
reaction/hypersensitivity  4 Discontinue suspected drug(s).  
Congestive heart failure 
(CHF)   Any Any participant with new symptoms of 
CHF worsening symptoms of baseline 
CHF or LVEF < 45% should have all 
drugs held until resolution or return to 
baseline regardless of attribution, once 
resolved Carfilzomib may continue at 
the original dose, reduced dose  or 
discontinued at the investigator's 
discretion, but PLD must be 
discontinued  
Creatinine Clearance  < 
15 mL/min (by Cockcroft -
Gault formula , see 
Appendix C)   N/A Hold all drugs until > 15mL/min 
regardless of attribution, then reduce 
suspected drug(s) by one dose level.  
Herpes simplex virus 
(HSV) or herpes zoster  Any Hold all drugs until HSV lesions are 
dry then resume treatment at full dose.  
 
Amendment 4 12/04/15   Page 28 of 60 
 Infection  > 3 Hold all drugs until infection is 
adequately controlled with systemic 
therapy regardless of attribution, then 
resume treatment at full doses. Patients 
with recurrent infection should have 
carfilzomib or PLD dose reduced at the 
investigator's discretion.  
Nausea, Vomiting, or 
Diarrhea      
persisting < 3 days 
following adequate 
treatment of antiemetics or 
antidiarrheal s 3 No dose modification required.  
      
persisting > 3 days 
following adequate 
treatment of antiemetics or 
antidiarrheals  3 Hold suspected study drug(s) until 
toxicity resolves to < grade 1 or 
baseline, then reduce suspected drug(s) 
by one dose level.  
Neuropathy      
Moderate symptoms; 
limiting instrumental ADL 
but not painful   2 Continue treatment. Patients on 
Pyridoxine should have it discontinued  
Moderate symptoms with 
associated pain; limiting 
instrumental ADL    2 Continue treatment. Patients on 
Pyridoxine should have it discontinued. 
If neuropathy persists for more than 
two weeks, hold suspected  drug(s) until 
resolved to < grade 2 without pain, then 
reduce suspected drug(s) by one dose 
level.  
      
Severe symptoms; limiting 
self care ADL  3 Continue treatment. Patients on 
Pyridoxine should have it discontinued. 
If neuropathy persists for more than 
two weeks, hold suspected drug(s) until 
resolved to < grade 2 without pain, then 
reduce suspected drug(s) by one dose 
level.  
   
  
Life-threatening 
consequences; urgent 
intervention indicated  4 Discontinue treatment.  
  
 
Amendment 4 12/04/15   Page 29 of 60 
 Palmar -Plantar 
Erythrodysthesia (PPE)  
Erythema, desquamation, 
or swelling interfering with 
but not precluding normal 
physical activities; small 
blisters or ulcerations less 
than 2 cm in diameter  2  First episode:  Hold all drugs until 
resolved to < grade 1 regardless of 
attribution, then resume at the same 
dose.  
Second episode:  Hold all drugs until 
resolved to < grade 1 regardless of 
attribution, then resume carfilzomib at 
same dose level a reduce PLD by one 
dose level . 
Third episode:  Hold all drugs  until 
resolved to < grade 1 regardless of 
attribution, then resume carfilzomib at 
same dose and discontinue PLD   
Blistering, ulceration, or 
swelling interfering with 
walking or normal daily 
activities; cannot wear 
regular clothing  3 First episode:  Hold all drugs until 
resolved to < grade 1 regardless of 
attribution, then resume carfilzomib at 
same dose level a reduce PLD by one 
dose level.  
    Second episode:  Hold all drugs until 
resolved to < grade 1 regardless of 
attribution, then resume carfilzomib at 
same dose and discontinue PLD.  
      
Diffuse or local process 
causing infectious 
complications, a bed -
ridden state or 
hospitalization  4 First episode:  Hold all drugs until 
resolved to < grade 1 regardless of 
attribution, then resume carfilzomib at 
same dose and discontinue PLD.  
Stomatitis  
Painful erythema, edema, 
or ulcers, but can eat  2 First episode:  Hold all drugs until 
resolved to < grade 1 then resume at 
the same dose.    
Second episode: Hold all drugs until 
resolved to < grade 1 then resume 
carfilzomib at the same dose and PLD 
at 20 mg/m2. 
Third episode: Hold all drugs until 
resolved to < grade 1 then discontinue 
PLD and resume carfilzomib at the 
same dose.   
Painful erythema, edema, 
or ulcers, and cannot eat  3 First episode: Hold all drugs until 
resolved to < grade 1 then resume 
carfilzomib at the same dose and PLD 
at 20 mg/m2. 
    Second episode: Hold all drugs until 
resolved to < grade 1 then discontinue 
PLD and resume carfilzomib at the 
 
Amendment 4 12/04/15   Page 30 of 60 
 same dose.  
      
Requires parenteral or 
enteral support  4 Hold all drugs until resolved to < grade 
1, then discontinue PLD and resume 
carfilzomib at the same dose.   
Tumor lysis syndrome, 
defined as > 3 of 
following:  Any Hold all drugs until all abnormalities in 
serum chemistries have resolved to 
baseline, then resume treatment at full 
doses.  
> 50% increase in 
creatinine      
> 50% increase in uric acid  
> 50% increase in 
phosphorus      
> 30% increase in 
potassium  
> 20% decrease in calcium  
> 2-fold increase in LDH      
Other non -hematologic 
toxicity  > 3 Hold suspected study drug(s) until 
toxicity resolves to <  grade 1 or 
baseline, then reduce suspected drug(s) 
by one dose level.  
 
6.3 Missed Doses  
 
Missed doses will not be replaced during a cycle . Doses can be adjusted by +/ - 2 days to 
allow for holidays, travel issues, etc. Additional adjustments may be granted at the PI’s 
discretion. Everything possible should be done to prevent adjustments from in the study 
schedule during Cycle 1.   
 
6.4 Changes in Body Surface Area (BSA)  
 
Dose adjustments do not need to be made for weight gai ns/losses of ≤  20% from baseline .  
Participants  with a Body Surface Area (BSA) of greater than 2.2 m2 will receive a capped 
dose using 2.2 m2 as the cut -off value.  
 
 
7.0 AGENT ADMINISTRATION  
 
7.1 Carfilzomib  
 
7.1.1 Accountability  
 
Instructions for the receipt, inspection, storage, preparation, administration, and 
disposal of Carfilzomib for Injection are provided in the Pharmacy Manual at 
each clinical site.  
 
Amendment 4 12/04/15   Page 31 of 60 
  
7.1.2 Availability  
 
Carfilzomib for injection is supplied as a lyophilized paren teral product in single -
use vials. Before use, the lyophilized product is reconstituted with water for 
injection to a final concentration of 2 mg/mL.  
 
7.1.3 Storage, Stability, and Preparation  
 
Lyophilized Carfilzomib for Injection is stored in a refrigerator at  2°C to 8°C. 
Carfilzomib doses are based on BSA. In a typical dose of carfilzomib, 27 mg/m2 
in a participant  with a BSA of 2.0 m2, the dose delivered would be 54 mg 
carfilzomib in a volume of 27 mL. Participants  with a BSA of 2.2 m2 or higher 
receive a dos e based upon 2.2 m2 BSA.  After addition of the appropriate amount 
of Water for Injection and vigorous mixing, the solution is administered as an IV 
infusion.    
 
7.1.4 Administration  
 
The dosing schedule of carfilzomib will be on Days 1, 2, 8, 9, 15, and 16 in a 28 -
day cycle for 6 cycles and then weekly (Days 1, 8, 15, and 22) thereafter  until 
disease progression  or clinical relapse . Participants treated prior to approval of 
amendment 1, will have carfil zomib administered on Days 1, 2, 8, 9, 15, and 16 
during Cycles 1 and 2 and on Days 1, 8, 15, and 22 beginning on Cycle 3.  
Carfilzomib dose levels being  investigated are: 20mg/m2, 20/27mg/m2, 
20/36mg/m2, 20/45mg/m2, and 20/56m g/m2.   
 
Current clinical experience indicates that carfilzomib can be safely administered 
as an IV push at rates of approximately 10 mL/minute for doses of 20 -27mg/m2.  
Higher doses (> 27 mg/m2) should be administered as a 30 -minute infusion. For 
IV infus ion over 30 minutes, carfilzomib  should be diluted into 50cc of 5% 
Dextrose Injection. USP (D5W) . Based on preclinical studies, these adjustments 
in infusion rate and time should not affect the PDn effects in humans . 
 
Each dose will consist of carfilzomib for injection administered on a mg/m2 basis, 
and should be based on the participant ’s actual calculated body surface area 
(BSA) at baseline.  Participants  with a BSA > 2.2 m2 will receive a dose based on 
a 2.2 m2 BSA.  
 
IV hydration will be given immediately before carfilzomib dose during Cycle 1.  
This will consist of 250 to 500 mL normal saline or other appropriate IV fluid.  
The goal of the hydration program is to maintain robust urine output ( e.g., ≥ 2 
L/day).  Participants  should be monitored periodically during this period for 
evidence of fluid overload.  
 
Patients not receiving dexamethasone as part of the regimen (those treated in part 
 
Amendment 4 12/04/15   Page 32 of 60 
 1 of phase 1) should receive 4mg dexamethasone premedication >30 minutes 
prior to all carfilzomib doses in c ycle 1. Dexamethasone premedication can 
continue beyond cycle 1 at the discretion of the treating physician. Patients being 
treated with 10 or 20 mg dexamethasone as part of their regimen should not 
receive an additional 4mg as premedication.   
 
Complete b lood counts (CBC) with platelet count should be obtained and 
reviewed prior to carfilzomib dosing.  See section 6.2.2  for guidelines for dose 
reductions, adjustments and delays  for hematologic  toxicities.  
 
Appropriate chemistries, including creatinine shoul d be obtained and reviewed 
prior to carfilzomib dosing  during cycles 1 and 2. Electrolyte abnormalities that 
are National Cancer Institute (NCI) Common Terminology Criteria for Adverse 
Events (CTCAE) >  2 or clinically significant should be corrected  prior to dosing .  
Renal function must be monitored closely duri ng treatment with carfilzomib. 
Carfilzomib must be held for participants  with a creatinine clearance (by 
Cockcroft -Gault formula see Appendix C) < 15 mL/min at any time during study 
participation.  
 
Participants  with laboratory abnormalities consistent with TLS should not receive 
the scheduled dose.  Lab abnormalities consistent with TLS is defined as > 3 of 
following : serum creatinine ≥ 50% increase, uric acid ≥ 50% increase, phos phorus  
≥ 50% increas e, potassium ≥ 30% increase, calcium ≥ 20% decrease , LDH ≥ 2 -
fold increase prior to dosing should not receive the scheduled dose.  Participants  
with such abnormalities should be re -evaluated again within the next 24 hours (or 
sooner, if clinically indicated) and then periodically as clinically indicated.    
 
Participants  should have a dedicated line for carfilzomib administration.  Before 
and aft er administration, the line must be flushed with a minimum of 20  mL of 
normal saline.  If a dedicated line is not possible, the existing line must be flushed 
with a minimum of 20  mL of normal saline before and after drug administration.     
 
Participants  may experience stinging , burning, or a painful sensation at the 
injection site during the IV push administration of carfilzomib. This generally is 
mild and subsides shortly following the infusion. Slowing the IV push to the 
maximum allowed tim e (10 minutes) can help with minimize such a reaction.  
 
Carfilzomib  is considered an irritant. Nonetheless, care should be taken to avoid 
extravasation. If any signs or symptoms of extravasation occur, the infusion 
should be terminated and restarted in an other vein. Apply ice immediately for 30 -
60 minutes, subsequently alternating on and off every 15 minutes for 24 hours. 
The extremity should be monitored for 24 -48 hours, then the participant may 
resume normal activity as tolerated. Do not apply heat or so dium bicarbonate. If 
pain, erythema  or swelling persists beyond 48 hours the participant should be 
referred to a plastic surgeon for possible debridement at the treating physician’s 
discretion.  
 
Amendment 4 12/04/15   Page 33 of 60 
  
The dose will be administered at  a facility capable of managi ng hypersensitivity 
reactions.  Medications to treat infusion -related reactions, as well as emergency 
equipment should be available for immediate use. If a patient develops a grade > 
2 infusion -related reaction, the infusion should be stopped  and appropriat e 
symptomatic treatment per institutional guidelines should be started immediately. 
The participant should be observed for at least 30 to 60 minutes depending on the 
severity of the reaction. At the discretion of the treating physician, treatment may 
be re sumed. Discontinue treatment if subsequent infusion -related reaction occurs.  
 
In the event of > grade 2 infusion -related  or hypersensitivity  reaction during  
carfilzomib infusion , discontinue the carfilzomib injection. Begin appropriate 
symptomatic treatment immediately per institutional guidelines.  The participant 
should be observed for at least 30 to 60 minutes depending on the severity of the 
reaction. At the discretion of the t reating physician, treatment may be resumed. 
Discontinue treatment if subsequent infusion -related reaction occurs.  
 
Procedures for dose reductions, adjustments and delays are summarized in 
Section 6.0. 
 
7.1.5 Guidelines for Monitoring and Tre atment of Tumor Lysi s Syndrome  
 
Tumor Lysis Syndrome ( TLS), which may be associated with multiorgan failure, 
has been observed in treatment Cycles 1 and 2 in some participants  with MM who 
have been treated with carfilzomib.  
 
7.1.5.1  Laboratory Monitoring  
 
Participants  with laboratory abnormalities consistent with TLS should not 
receive the scheduled dose.  Lab abnormalities consistent with TLS is 
defined as > 3 of following : serum creatinine ≥ 50% increase, uric acid ≥ 
50% increase, phos phorus  ≥ 50% increase, potassium  ≥ 30% increase, 
calcium ≥ 20% decrease , LDH ≥ 2 -fold increase prior to dosing should not 
receive the scheduled dose.  Participants  with such abnormalities should 
be re -evaluated again within the next 24 hours (or sooner, if clinically 
indicated) and then periodically as clinically indicated.    
 
7.1.5.2  Clinical Monitoring  
 
Inform participants  of signs and symptoms that may be indicative of TLS, 
such as fevers, chills/rigors, dyspnea, nausea, vomiting, muscle tetany, 
weakness, or cramping, seizures, and decreased urine output.  Advise 
participants  to report such symptoms immediately and seek medical 
attention.  
 
7.1.5.3  Treatment  of Tumor Lysis Syndrome  
 
Amendment 4 12/04/15   Page 34 of 60 
  
If TLS occurs, cardiac rhythm, fluid, and serial laboratory monitoring 
should be instituted.  Correct electrolyte abnorm alities, monitor renal 
function and fluid balance, and administer therapeutic and supportive care, 
including dialysis, as clinically indicated.  
 
A “first -dose effect” has been seen, which is notable for fever, chills, 
and/or rigors occurring during the eve ning following the first day of 
infusion and an increase in creatinine on Day 2, which may be the clinical 
sequelae of rapid tumor lysis and/or cytokine release.  Should a “first 
dose” effect occur at any point during Cycle 1 or 2, treatment with high 
dose glucocorticoids (e.g. methylprednisolone 50 –100 mg) is 
recommended.  In addition, intravenous fluids, vasopressors, oxygen, 
bronchodilators, and acetaminophen should be available for immediate use 
and instituted, as medically indicated.  
 
7.2 Pegylated Liposo mal Doxorubicin (Doxil®  or Lipodox ) 
 
7.2.1 Accountability  
 
Instructions for the receipt, inspection, storage, preparation, administration, and 
disposal of pegylated liposomal doxorubicin  (PLD)  are provided in the Pharmacy 
Manual at each clinical site.  
 
7.2.2 Availability  
 
Pegylated liposomal doxorubicin  (PLD)  is supplied in 20mg and 50mg vials as a 
liposomal dispersion at a concentration of 2mg/ml. Vials are intended for single 
use.  
 
7.2.3 Storage and Stability  
 
Intact vials of pegylated liposomal doxorubicin  (PLD)  should be stored under 
refrigeration (2 -8ºC). Pro longed freezing may adversely affect liposomal drug 
products, but freezing for less than one month doesn’t seem to do so. Pegylated 
liposomal doxorubicin  (PLD)  diluted for infusion is stable for 48 hours under 
refrigeration or 24 hours at room temperature.    
 
7.2.4 Preparation  
 
The desired volume of liposomal dispersion should be withdrawn and must be 
added to 250ml D5W for IV infusion.   
  
 
Amendment 4 12/04/15   Page 35 of 60 
  
7.2.5 Administration   
 
PLD will be administered on Day 8 of each 28 -day cycle for a maximum of 6 
cycles. PLD dose levels being investigated are: 20mg/m2, and 30mg/m2.   
 
Pegylated liposomal doxorubicin (PLD) will be administered as an IV infusion 
over 1 hour beginning  one hour after the  beginning of the carfilzomib  infusio n.  
On days when carfilzomib is held, PLD should also be held . PLD may be 
administered throug h the same line as carfilzomib. Rapid flushing of the infusion 
line should be avoided  post PLD administration .  
 
Pegylated liposomal doxorubicin  (PLD)  is considered an irritant. This is in 
contrast to conventional doxorubicin which can cause severe tissue damage on 
extravasation, Nonetheless, care should be taken to avoid extravasation. If any 
signs or symptoms of extravasation occur, the infusion shoul d be terminated and 
restarted in another vein. Apply ice immediately for 30 -60 minutes, subsequently 
alternating on and off every 15 minutes for 24 hours. The extremity should be 
monitored for 24 -48 hours, then the participant  may resume normal activity as  
tolerated . Do not apply heat or sodium bicarbonate. If pain, erythema  or swelling 
persists  beyond 48 hours the participant  should be referred to a plastic surgeon for 
possible debridement at the treating physician’s  discretion.  
 
Infusion -related reactions have been seen in up to 10% of participants  per the 
manufacturer. Participants  who experience this reaction  generally do so during the 
first infusion  and not with subsequent dosing . Symptoms may include fever, 
flushing, dyspnea, facial sw elling, headache , chills, back pain, tightness in the 
chest and throat, rash, pruritus , chest pain, hypotension, syncope, sinus 
tachycardia, apnea, bronchospasm/wheezin g, cyanosis, and  asthma. Serious and 
sometimes life -threatening or fatal anaphylactic sh ock/anaphylactoid reactions 
have been reported . 
 
Rapid infusion may increase the risk of some infusion -related reactions, and it is 
suggested that first infusion b e initiated at a rate of 1 mg/min . If no reactions are 
observed after 5 -10 minutes, the rate can be increased to complete the infusion 
over 1 hour.   
 
The dose will be administered at  a facility capable of managing hypersensitivity 
reactions.  Medications to treat infusion -related reactions, as well as emergency 
equipment, should be available for immediate use. If a participant develops a 
grade > 2 infusion -related reaction, the infusion should be stopped  and 
appropriate symptomatic treatment per institut ional guidelines should be started 
imme diately. The participant should be observed for at least 30 to 60 minutes 
depending on the severity of the reaction. At the discretion of the treating 
physician, treatment may be resumed with administration of H 1-blockers and/or 
steroids. Discontinue treat ment if subsequent infusion -related reaction occurs.  
 
Amendment 4 12/04/15   Page 36 of 60 
  
Procedures for dose reductions, adjustments and delays are summarized in 
Section 6.0. 
 
7.2.6 Palmar -Plantar Erythrodysesthesia  (PPE)  
 
The onset of PPE is often preceded by exposure of the affected area to friction 
and/or heat. All participants  should therefore be advised to avoid contact with 
heated objects or bathing and washing with hot water during therapy.  
 
Pyridoxine  (vitamin B6) has been reported to decrease the severity of PPE and 
may decrease its incidence if used in a prophylactic setting. Participants  in this 
study should  receive pyridoxine starting on or before D ay 1 of Cycle 1 [36, 37]  
(See section 6.3.2 for details ). 
 
Management of PPE once it has appeared is predominantly supportive, with use 
of treatments such as topical wound care, cold compresses, and  elevation. Non -
steroidal anti -inflammatory drugs are beneficial in some, and topical 99% 
dimethyl -sulfoxide has been reported to be of benefit as well , but none of these 
studies have been studied in a randomized, blinded, prospective fashion. 
Pyridoxine w ill be continued in the event that PPE develops despite prophylaxis  
[38].  
 
7.3 Dexamethasone  
 
7.3.1 Accountability  
 
Dexamethasone is not provided by the study. It will be sourced from a 
commercial pharmacy.   
 
7.3.2 Availability  
 
Dexamethasone is commercially available in 0.25 mg, 0.5 mg, 0.75 mg, 1 mg,  
1.5mg, 4 mg, and 6 mg tablets. It is also available as a 0.5 mg/5mL elixir, and as 4 
mg/mL, 10 mg/mL, and 20 mg/mL solution for injection. Please refer to the FDA 
approved package insert  for dexamethasone for product information, extensive 
preparation instructions, and a comprehensive list of adverse events.  
 
7.3.3 Storage and Stability  
 
Dexamethasone tablets should be stored at room temperature . Solution for 
injection may be administered dil uted in IV fluids over 10 -20 minutes .   
 
7.3.4 Administration   
 
Dexamethasone will be administered on the same dosing schedule as carfilzomib 
 
Amendment 4 12/04/15   Page 37 of 60 
 (Days 1, 2, 8, 9, 15, and 16 for 6 cycles and then Days 1, 8, 15, and 22 thereafter  
until disease progression or clinic al relapse ). Dexamethasone dose levels being 
investigated are: 10 mg and 20mg.  
 
Dexamethasone should be taken IV or PO > 30 minutes prior to Carfilzomib 
injection.  
 
After cycle 2, participants enrolled into part 1 of phase 1 (those not receiving 
dexamethasone) can have dex amethasone 20mg added at the discretion of the 
treating physician. If dex amethasone is added, the dose modification guidelines 
(section 6.2) should be followed.  
 
7.4 General Concomitant Medication and Supportive Care Guidelines  
 
7.4.1 HSV Prophylaxis  
 
Acyclovir, or valacyclovir, should be given to all participants , per institutional 
prophylaxis guidelines, unless contraindicated.  
 
7.4.2 Pyridoxine  
 
It is recommended that all participants  be initiated on pyridoxine (vitamin B6) at 
200 mg PO QD for prophylaxis against palmar plantar erythrodysesthesia (PPE) 
starting on or before Day 1 of Cycle 1. Pyridoxine will be continued in the event 
that PPE develops despite prophylaxis   
 
Vitamin B6 has been reported to cause neuropathy [39]. Therefore any participants  
who develop a neuropathy more severe than grade 1 while on study should first 
have this agent discontinued.    
 
7.4.3 Glucocorticoids  
 
Glucocorticoids (other than those required per protocol) are permitted for non -
malignant conditions (i.e. asthma, IBD, etc.) but should not be used unless  
completely  necessary . Glucocorticoids have anti -myeloma effect that may lead to 
confusion of the response data for this study. Glucocorticoid use while one study 
should be kept minimal.   
 
7.4.4 Bisphosphonates  
 
Participants  should receive therapy with bisphosphonates as per institutional 
guidelines. The choice of agents in this category will be left to the discretion of 
the treating physicians.   
  
 
Amendment 4 12/04/15   Page 38 of 60 
  
7.4.5 Erythropoietins   
 
Participants  may develop new or worsening ane mia and may require either 
initiation of an erythropoietin preparation or an increased dose of the agent they 
are already receiving . The choice of preparations to be used will be left to the 
discretion of the treating physicians.  
 
7.4.6 Filgrastim (G -CSF), Peg -Filgrastim, and Sargramostim (GM -CSF)  
 
Participants  may develop neutropenia and may benefit from initiation of some 
type of colony stimulating factor , but they should not be given prophylactically . 
The choice of preparations to be used will be left to the discretion of the treating 
physicians.  
 
7.4.7 Platelet, RBC, Whole blood, or FFP Transfusions  
 
Participants  may receive platelet , red blood cell (RBC),  whole blood,  or fresh 
frozen plasma (FFP) transfusions if clinically indicated .   
 
7.4.8 Anti emetics and A ntidiarrheals  
 
Carfilzomib and PLD treatment can cause nausea, vomiting, or diarrhea, 
sometimes requiring the use of antiemetics or antidiarrheals, but these agents 
should not be started prophylactically. If needed, the choice of preparations to be 
used w ill be left to the discretion of the treating physicians.  
 
Participants  with severe nausea, vomiting, or diarrhea should have f luid and 
electrolyte replacement administered to prevent dehydration  per institutional 
guidelines .   
 
7.4.9 Palliative  Radiation  
 
Palliative  radiation while on study is allowed at the discretion of the treating 
physician  as long as the definition of progressive disease is not met (see section 
9.8). Participants  meeting the definition of progressive disease should be 
discontinued from  study.  
 
7.4.10  Anti -Myeloma Therapy  
 
The concurrent use of any approved or investigative drug with known or 
suspected anti-myeloma effect  outside the scope of this trial is prohibited, with 
exception to those specifically permitted in section 7.4.   
  
 
Amendment 4 12/04/15   Page 39 of 60 
  
7.4.11  Investigational Agents  
 
Other investigative agents (e.g., antibiotics or antiemetics ) should not be used 
during the study.  
 
 
8.0 DURATION  OF THERAPY  
 
8.1 Criteria for Removal from Study  
  
Treatment may  continue  until disease progression or clinical relapse , as defined in 
Sections 9.8 and 9.9 respectively, or until one or more of the following  criteri on applies:  
 
• Participant  withdraws consent  
• Holding study drug(s) >  2 continuous weeks for adverse event(s)  
• Adverse event(s) that, in the judgment of the Investigator, may cause severe or 
permanent harm or which rule out continuation of study drug.  
• General or specific changes in the participant’s  condition render the 
partici pant unacceptable for further treatment in the judgment of the 
investigator  
• Suspected or confirmed pregnancy  
• Major violation of the study protocol  
• Participant  lost to follow -up 
• The PI decides to remove the participant  from study  for any reason  
• Death  
• The treating center  decides to close the study  
 
8.2 Duration of Follow -Up 
 
Participants  will be followed for 18 months after removal from study or until death, 
whichever occurs first.  Participants  removed from study for unacceptable adverse events 
will be followed until resolution or stabilization of the adverse event , even if the follow -
up exceeds 18 months . 
 
 
9.0 CRITERIA FOR RESPONSE  
  
9.1 Complete Response  
 
Complete response (CR) requires all of the following:  
  
• Disappearance monoclonal protein  by both protein electrophoresis and 
immunofixation studies from the blood and urine on at least two 
determinations, performed a minimum of six weeks apar t 
• <5% plasma cells in the bone marrow  
 
Amendment 4 12/04/15   Page 40 of 60 
 • Disappearance of soft tissue plasmacytomas for at least six weeks  
  
9.2 Stringent Complete Response  
 
Stringent complete r esponse ( sCR) requires all of the fol lowing:  
 
• CR as defined above  
• Normal free light chain ratio  
• Absence of clonal cells in the bone marrow by immunohistochemistry or 
immunofluorescence  
 
9.3 Near -Complete Response  
 
Near -complete response ( nCR) requires all of the following:  
 
• The presence of a residual monoclonal protein that is visible only on 
immunofixation studies, and not on serum or urine protein electrophoresis  
• All other criteria are met for complete response.  
 
9.4 Very Good Partial Response  
 
Very good partial  response ( VGP R) requires all of the following:  
 
• Serum and urine monoclonal protein detectable by immunofixation but not on 
electrophoresis for at least two determinations, perform ed a minimum of six 
weeks apart   
     OR   
> 90% reduction in serum monoclonal protein with urine monoclonal protein 
< 100 mg per 24 hours  for at least two determinations, performed a minimum 
of six weeks apart.  
• If present, > 50% reduction in the size of soft tissue plasmacytomas (by 
clinical or radi ographic examinations) for at least six weeks.  
 
9.5 Partial Response  
 
Partial response (PR) requires all of the following:  
 
• > 50% reduction in the level of the serum monoclonal protein for at least two 
determinations performed a minimum of six weeks apart.  
• Reduction in urine  monoclonal protein by either > 90% or to < 200 mg for at 
least two determinations performed a minimum of six weeks apart.  
• If present, > 50% reduction in the size of soft tissue plasmacytomas (by 
clinical  or radiographic examinations) for at least six weeks.  
• If serum and urine monoclonal protein are unmeasurable, a >50% decrease in 
difference between the involved and uninvolved free light  chain levels is 
required in place of monoclonal protein criteria  (The absolute de crease must 
 
Amendment 4 12/04/15   Page 41 of 60 
 be > 10 mg/dl)  
• If serum and urine monoclonal protein are unmeasurable and serum free light 
chain is unmeasurable,  a > 50% reduction in plasma cells is required i n place 
of monoclonal protein provided that baseline bone marrow plasma cell 
percentage was > 30%  
 
9.6 Minimal Response  
 
Minimal  response ( MR) requires all of the following:  
 
• > 25% to <  49% reduction in the level of serum monoclonal protein for at 
least two determinations six weeks apart.  
• If present, a 50 to 89% reduction in 24 -hour urin e monoclonal protein  which 
still exceeds 200 mg/24hr, for at least two determinations six weeks apart .  
• 25-49% reduction in the size of plasmacytomas (by clinical or radiographic 
examinations) for at least six weeks.   
• No increase in size or number of lytic bone lesions (development of 
compression fracture dose not exclude response).  
 
Note:  MR includes participants  in whom some but not all criteria for PR are fulfilled 
providing the remaining criteria satisfy the requirements for MR.  
 
9.7 Stable Disease  
 
Stable disease (SD) is defined as not meeting criteria for any other response as defined in 
this section.  
 
9.8 Progressive Disease  
 
Progressive disease (PD) requires one or more of the following:  
  
• > 25% increase in the level of serum monoclonal protein , which must also be 
an absolute increase of at least 0.5 g/dL, and confirmed on a repeat 
investigation.   
• > 25% increase in 24 -hour urine monoclonal protein , which must also be an 
absolute increase of at least 200 mg/24hr and confirmed on a repeat 
investi gation.   
• > 25% increase in plasma cells in a bone marrow aspirate or on trephine 
biopsy, which must also be an absolute increase of at least 10%.  
• > 25% increase in the difference between involved and uninvolved free light 
chain levels (The absolute incre ase must be >10 mg/dl)  
• Definite increase in the size of existing lytic bone lesions or soft tissue 
plasmacytomas. A definite increase is defined as at least 50% (and at least 1 
cm) increase as measured serially as the sum of the products of the cross -
diam eters of the lesions . 
• Development of new bone lesions or soft tissue plasmacytomas (not including 
 
Amendment 4 12/04/15   Page 42 of 60 
 compression fracture).  
• Development of hypercalcemia (corrected serum calcium > 11.5 mg/dL or 2.8 
mmol/L not attributable to any  cause  other than progressive multiple 
myeloma ).  
 
Note:  A response of progressive disease nullifies any other concurrent response. For 
example, at a given time point a participant  meets criteria for VGPR but has d evelopment 
of new bone lesions  the response is PD not VGPR . 
  
9.9 Clinical Relapse  
 
Clinical relapse (i.e. progressive disease requiring alternate myeloma treatment)  requires 
one or more of the following : 
 
• Decrease in hemoglobin > 2 g/dl not attributable to any cause  other than 
progressive  multiple myeloma  
• Increase in creatinine  by > 2 mg/dl not attributable to any cause  other than 
progressive multiple myeloma  
• Other worsening laboratory result, or clinical condition that the treating 
physician determines  is not attributable to any cause  other than progressive 
multiple myeloma  
 
9.10 Relapse from C omplete Response  
 
Relapse from a complete response requires a prior CR or sCR as described above and 
subsequently developing one or more of the following:  
 
• Reappearance  of serum or urinary paraprotein on immunofixation or routine 
electrophoresis excluding oligoclonal immune reconstitution for at least two 
determinations .  
• > 5% plasma cells in the bone marrow aspirate or biopsy.  
 
 
Amendment 4 12/04/15   Page 43 of 60 
 10.0 STUDY CALENDAR  
 
Assessment  * Screening  a Cycles 1 through 6  Cycles 7 and beyond  End of 
Study b Follow -
up c D1 D2 D8 D9 D15 D16 D1 D8 D15 D22 
Sign informed consent  X             
Medical & treatment history  X             
Vital signs d X X X X X X X X X X X   
Physical exam e X X1      X      
Toxicity assessment  X X X X X X X X X X X X  
CBC w/ diff erential  X X  X  X  X X X X X  
Chemistries  f  X X X X X X X X X X X X  
PT/INR & PTT  X X1            
SPEP & IFIX g X X1    X2  X    X  
24-hour urine  total p rotein, UPEP, & IFIX  gh X X1    X2  X    X  
Serum free light chains  X X1    X2  X    X  
Quantitative immunoglobulins (IgA, IgG, IgM)  X X1    X2  X    X  
Beta-2 microglobulin  X X1      X    X  
Serum HCG j X X      X    X  
EKG  & Chest x -ray X             
MUGA or Echo  m X             
Imaging for plasmacytoma assessment km X           X3  
Skeletal survey m X           X3  
Bone marrow biopsy & aspirate n X           X3  
Correlative samples o X           X3  
Carfilzomib administration   X X X X X X X X X X   
PLD administration     X          
Dexameth asone administration p  X X X X X X X X X X   
Follow -up for survival              X 
* All assessments allowed a window of +/ - 2 days for scheduling issues (such as holidays)  
a: Screening period is D-21 though D1 prior to Carfilzomib dose  
b: End of study must be within 30 days of last dose of study drug  
c: Follow -up takes place every 3 months for up to 18 months or until resolution or stabilization  of adverse event s, whichever is longer  
d: To be done within 1 hour prior to  carfilzomib administration . 
e: Physical exam includes height, weight, BSA, performance status , neurological assessment  and plasmacytoma assessment  if indicated  . 
f: Chemistries include Complete Metabolic Panel  with Renal and Hepatic Panels , LDH, Magnesium, Phosphorous, Uric Acid . 
g: SPEP = serum protein electrophoresis , IFIX=immu nofixation, UPEP= urine protein electrophoresis . 
h: All participants  must complete 24 hour urine at screening and for confirmation of CR or VGPR if necessary. Additional serial 24 -hour urines only required for participants  with > 0.2g/24 hours of 
monoclona l protein at screening.   
j: Required only in women of childbearing potential; 2 negative test results required before study drug dosing on Cycle 1 Day  1. 
k: Only required if clinically indicated . Imaging can include X -ray, CT, MRI, PET, etc.  
m: To be repeated on study when clinically indicated . 
n: Bone marrow aspirate and core biopsy for differential, cytogenetics, and fluorescent in situ hybridization (FISH) studies . To be repeated on study for confirmation of CR or sCR.  
o: To be repeated on study whenever a bone marrow biopsy and aspirate is performed . 
p: Only for patients treated in part 2 of phase 1 or phase 2.  
1: Not required to be repeated  in Cycle 1 if screening assessment was within 7 days of Day 1 . 
2: Only during Cycle 1 . 
3. Optional. If patient is willing and able.  
 
Amendment 4 12/04/15   Page 44 of 60 
 11.0 DATA SUBMISSION SCHEDULE  
 
Case Report Form  Submission Schedule  
Original Consent  
Registration  
Eligibility Checklist  
Medical History  
Treatment History  
Radiation History  
Transplant History  
Vital Signs  
Labs – Hematology  
Labs – Chemistry  
Disease Assessment  
Skeletal Survey/Plasmacytoma Evaluation  
Bone Marrow Biopsy  Original Consent : Before initiat ion of any 
non-standard of care procedures  
 
Registration and Eligibility Checklist : At 
time of enrollment   
 
All others : Within 28 days of enrollment  
 
Vital Signs  
Labs – Hematology  
Labs – Chemistry  
Disease Assessment  
Response Assessment  
Skeletal Survey/Plasmacytoma Evaluation  
Bone Marrow Biopsy  
Study Drug Dosing Record  Within 28 days of end of each cycle  
 
Note : Some forms must be completed 
multiple times per cycle  
 
Correlative Studies  Within 28 days of sample collection  
 
Adverse Events  To be completed throughout study 
participation; as per guidelines in section 
13.1 
 
Off Study  
Vital Signs  
Labs – Hematology  
Labs – Chemistry  
Disease Assessment Form  
Response Assessment Form  
Skeletal Survey/Plasmacytoma Evaluation  
Bone Marrow Biopsy Form  Within 28 days of end of study visit  
 
Survival Form  Within 28 days of follow -up 
 
  
 
Amendment 4 12/04/15   Page 45 of 60 
 12.0 CORRELATIVE STUDIES  
 
Bone marrow and peripheral blood samples will be taken prior to treatment , at time of 
complete response, and/or at end of study.  
 
The following samples will be collected at all time points : 
• Bone marrow aspirate: 6 -10 mL divided between two EDTA (lavender t op) tubes . 
• Peripheral blood for viable PBMC: 60 mL collected in 6 large EDTA (lavender 
top) tubes . 
• Peripheral blood for plasma: 10 mL collected in 1 EDTA (lavender top) tube.  
 
Bone marrow aspirate samples will be pooled, and mononuclear cells will be purified 
over Ficoll.  Resulting BM mononuclear cells will be divided into 1) viable cells 
cryopreserved at 107/vial, and 2) cell pellet for nucleic acid.  Plasma and from bone 
marrow will be divided into 2mL aliquots and frozen at -80oC.   
 
Peripheral blo od mononuclear cells (PBMC) will similarly be isolated by Ficoll 
prepar ation from the pooled peripheral blood lavender top tubes and will be viably 
cryopreserved.   
 
Plasma will be divided into 2mL aliquots and frozen at -80oC.   
 
Fresh PBMC or BM mononuclear cells may also be used for correlative studies at the 
discretion of the princip al investigator.   
 
All samples are to be delivered to the Siteman Cancer Center Tissue Procurement Core 
(Dr. Mark Watson, Director) during their normal operating ho urs.  Specimens will be 
identified by initials and study number at the Tissue Procurement Core, and samples will 
be processed appropriately.  
 
Contact information for questions regarding sample procurement only:   
 
Mark Watson, M .D., Ph.D. 
Siteman Cancer C enter Tissue Procurement Facility  
BJC Institute of Health  
5th Floor, Rooms 5120, 5113, and 5205 St Louis, MO 63110  
Phone: 314 -454-7615  
Fax: 314 -454-5525  
Email: tbank@w udosis.wustl.edu  
  
 
Amendment 4 12/04/15   Page 46 of 60 
 13.0 SAFETY MONITORING , DATA AUDITING , AND  REQUIRED  
REPORTING OF EVENTS  
 
13.1 Adverse Event s  
 
Definition:  any unfavorable medical occurrence in a human subject including 
any abnormal sign, symptom, or disease.  
 
Grading:  the descriptions and grading scales found in the r evised NCI Common 
Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized 
for all toxicity reporting.  A copy of the CTCAE version 4.0 can be downloaded 
from the CTEP website.  
 
Attribution (relatedness), Expectedness, and Seriousness: the definitions for 
the terms listed that should be used are those provided by the Department of 
Health and Human Services’ Office for Human Research Protections (OHRP).  A 
copy of this guidance can be found on OHRP’s website:  
(http://www.hhs.gov/ohrp/policy/AdvEvntGuid.htm ).   
 
All AEs , regardless of relationship to study drug, will be followed from first day 
of study treatment until  30 days following the last day of s tudy treatment or until 
the start of a new chemotherapy, whichever is sooner. All AEs resulting in death 
within 30 days following the last day of study treatment will be recorded without 
regards to new chemotherapy. Thereafter, any death while off study bu t 
reasonably related to study drug(s) will be recorded, regardless of the proximity to 
study treatment.  
 
All AEs should be recorded in the Case Repor t Forms (CRFs). The CRFs should 
include the duration, outcome, intensity, attribution, dose delays/dose 
modifications, and seriousness.   
 
The descriptions and grading scales found in the revised NCI Common 
Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized 
for all toxicity reporting  (see Appendix D).  
 
13.1.1  Regulatory Reporting of Internal AEs  
 
When a trend of unexpected and reasonably related non-serious AEs is 
identified by the PI, these events are required to reported to Amgen , 
HRPO, QASMC, and the FDA in a written  report (Medwatch 3500 form , 
see Appendix E). The events should be  then added to the consent form.  
 
All grade 3 and 4 AE s that are serious and/or unexpected and reasonable 
related must be reported  to Amgen , HRPO, QASMC, and  the FDA in a 
written report (Medwatch 3500 form, s ee Appendix E).  
 
 
Amendment 4 12/04/15   Page 47 of 60 
 All g rade 5  (death)  AEs must b e reported to Amgen , HRPO, QASMC , and 
the FDA in a written report (Medwatch 3500 form, see Appendix E ). 
 
13.1.2  Regulatory Reporting of External AEs  
 
Any event or summary of adverse events that are provided to the 
investigator or study chair  should be submitted t o QASMC and/or HRPO 
for review.  
 
13.2 Unanticipated Problems  
 
Definition:  
 
• unexpected (in terms of nature, severity, or frequency) given (a) the 
research procedures that are described in the protocol -related documents, 
such as the IRB -approved research protocol and informed consent 
document; and (b) the characteristics of the subject population being 
studied;  
• related or possibly related to participation in the research (in this guidance 
document, possibly related means there is a reasonable poss ibility that the 
incident, experience, or outcome may have been caused by the procedures 
involved in the research); and  
• suggests that the research places subjects or others at a greater risk of 
harm (including physical, psychological, economic, or social h arm) than 
was previously known or recognized.  
 
13.3 Noncompliance  
 
Definition:  failure to follow any applicable regulation or institutional policies that 
govern human subjects research or failure to follow the determinations of the 
IRB.   Noncompliance may occur  due to lack of knowledge or due to deliberate 
choice to ignore regulations, institutional policies, or determinations of the IRB.  
 
13.4 Serious Noncompliance  
 
Definition:  noncompliance that materially increases risks, that results in 
substantial harm to partic ipants  or others, or that materially compromises the 
rights or welfare of participants.  
 
13.5 Protocol Exceptions  
 
Definition:  A planned  deviation from the approved protocol that are under the 
research team’s control.  Exceptions apply only to a single participant or a 
singular situation.  
 
Pre-approval of all protocol exceptions must be obtained prior to the event, unless 
 
Amendment 4 12/04/15   Page 48 of 60 
 taken to avoid or eliminate immediate harm to a participant/participants. If taken 
to avoid or elim inate immediate harm to a participant report within 24 hours.  
 
13.6 Pregnancy  
 
Pregnancy of a female participant  or the female partner of a mal e participant  
while enrolled on this clinical trial or up to three months following administration 
of study drug(s)  is a reportable event  (Medwatch 3500 form, See Appendix  E). If 
the participant  is on study drug(s) at the time of pregnancy it must be discontinued 
immed iately.  
 
The pregnant female  will be followed until completion of the pregnancy.  The 
Investigator will be required to report the results of the pregnancy  (follow -up to 
the original Medwatch 3500  form ). 
 
If the outcome of the pregnancy meets a criterion f or immediate classification as a 
grade 5 event —spontaneous abortion (any congenital anomaly detected in an 
aborted fetus is to be documented), stillbirth, neonatal death, or congenital 
anomaly —the Investigator should r eport the event per the guidelines  below. 
 
13.7 Reporting to the Human Research Protection Office (HRPO) and the  
Quality Assurance and Safety Monitoring Committee ( QASMC) at  
Washington University  
 
The PI is required to promptly notify the IRB of the following events:  
 
• Any unanticipated problems involving risks to participants or others which 
occur at WU, any BJH or SLCH institution, or that impacts participants or 
the conduct of the study.  
• Noncompliance with federal regulations or the requirements or 
determinations of the IRB.  
• Receipt of  new information that may impact the willingness of participants 
to participate or continue participation in the research study.  
 
These events must be reported to the IRB within 10 working days  of the 
occurrence of the event or notification to the PI of th e event.   The death of a 
research participant that qualifies as a reportable event should be reported within 
1 working day  of the occurrence of the event or notification to the PI of the 
event.  
 
13.8 Reporting to the FDA  
 
The conduct of the study will comply with all FDA safety reporting requirements.  
PLEASE NOTE THAT REPORTING REQUIREMENTS FOR THE FDA 
DIFFER FROM REPORTING REQUIREMENTS FOR HRPO/QASMC.  It 
 
Amendment 4 12/04/15   Page 49 of 60 
 is the responsibility of the investigator to report any unanticipat ed problem to the 
FDA as follows:  
 
• Report any unexpected fatal or life -threatening adverse experiences 
associated with use of the drug (i.e., there is a reasonable possibility that 
the experience may have been caused by the drug) by telephone or fax no 
later than 7 calendar days  after initial receipt of the information.  A life-
threatening adverse experience  is defined as any adverse drug experience 
that places the subject (in the view of the investigator) at immediate risk of 
death from the reaction as it occurred, i.e., it does not include a reaction 
that, had it occurred in a more severe form, might have caused death.  
• Report any serious, unexpected adverse experiences, as well as results 
from animal studies that suggest significant clinical risk within 15 
calendar days  after initial receipt of this information.  A serious adverse 
drug experience  is defined as any adverse drug experience occurring at 
any dose that results in any of the following outcomes:  
o Death  
o A life -threatening adverse drug experience  
o Inpatient hospitalization or prolongation of existing hospitalization  
o A persistent or significant disability/incapacity (i.e., a substantial 
disruption of a person’s ability to conduct normal life functions)  
o A congenital anomaly/birth defect  
o Any other experie nce which, based upon appropriate medical 
judgment, may jeopardize the subject and may require medical or 
surgical intervention to prevent one of the outcomes listed above  
An unexpected adverse drug experience  is defined as any adverse drug 
experience, the specificity or severity of which is not consistent with the 
current investigator brochure (or risk information, if an IB is not required 
or available).  
 
All MedWatch forms will be sent by the investigator or investigator’s team to the 
FDA at the following address or by fax:  
 
Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Oncology Drug Products  
5901 -B Ammendale Rd.  
Beltsville, MD 20705 -1266  
FAX: 1 -800-FDA -0178  
 
13.9 Reporting to Amg en 
 
All required f orms will be sent to Amgen Global Safety  by Fax: (1-888) 814-
8653 , or at the following email address  (with secure email connection with 
Amgen only) : svc-ags-in-us@amgen.com .  
 
 
Amendment 4 12/04/15   Page 50 of 60 
 13.10  Timeframe for Reporting Required Events  
 
Deaths  
Any reportable  death while on study or within 30 
days of study  Immediately, within 24 hours, 
to PI, FDA, Amgen , and the 
IRB 
Any reportable  death while off study  Immediately, within 24 hours, 
to PI, FDA, Amgen , and the 
IRB 
Adverse Events/Unanticipated Problems  
Any reportable  adverse events as described in 
Sections 1 2.1 and 1 2.2 (other  than death)  Immediately, within 24 hours 
to PI, FDA, and within 10 
working days to the IRB  
All adverse events regardless of grade and attribution 
should be  submitted cumulatively  Include in DSM report  
Non-Compliance and Serious Non -Compliance  
All noncompliance and serious noncompliance as 
described in Sections 1 2.3 and 1 2.4 Immediately, within 24 hours, 
to PI and within 10 working 
days to the IRB 
Pregnancy  
Pregnancy  Immediately, within 24 hours, 
to PI, FDA, Amgen , and the 
IRB 
 
 
14.0 DATA AND SAFETY MONITORING PLAN  
 
In compliance with the Washington University Institutional Data and Safety Monitoring 
Plan, the Principal Investigator will provide a Data and Safety Monitoring (DSM) report 
to the Washington University Quality Assurance and Safety Monitoring Committee 
(QASMC) semi -annually beginning six months after accrual has opened (if at least five 
patients have been enrolled) or one year after accrual has opened (if fewer than five 
patients have been enrolled at the six -month mark).  
 
During the phase I  dose escalation, the Principal Investigator will review all patient data 
at least monthly (or before each dose -escalation if occurring soon er than monthly), and 
provide a semi -annual report to the Quality Assurance and Safety Monitoring Committee 
(QASMC).  During the phase II , the Principal Investigator will review all patient data at 
least every six months, and provide a semi -annual report t o the QASMC. This report will 
include:  
• HRPO protocol number, protocol title, Principal Investigator name, data 
coordinator name, regulatory coordinator name, and statistician  
• Date of initial HRPO approval, date of most recent consent HRPO 
approval/revision , date of HRPO expiration, date of most recent QA audit, study 
status, and phase of study  
 
Amendment 4 12/04/15   Page 51 of 60 
 • History of study including summary of substantive amendments; summary of 
accrual suspensions including start/stop dates and reason; and summary of 
protocol exceptions , error, or breach of confidentiality including start/stop dates 
and reason  
• Study -wide target accrual and study -wide actual accrual  
• Protocol activation date  
• Average rate of accrual observed in year 1, year 2, and subsequent years  
• Expected accrual end date and accrual by cohort  
• Objectives of protocol with supporting data and list the number of participants 
who have met each objective  
• Measures of efficacy  
• Early stopping rules with supporting data and list the number of participants w ho 
have met the early stopping rules  
• Summary of toxicities separated by cohorts with the number of dose -limiting 
toxicities indicated  
• Abstract submissions/publications  
• Summary of any recent literature that may affect the safety or ethics of the study  
 
The study principal investigator and Research Patient Coordinator will monitor for 
serious toxicities on an ongoing basis. Once the principal investigator or Research Patient 
Coordinator becomes aware of an adverse event, the AE will be reported to the HRPO 
and QASMC according to institutional guidelines.  
 
14.1 External Data Auditing  
 
The study data will be audited  by a member of the QASMC office on annual basis 
as per institutional guidelines.  
 
 
15.0 ENDPOINTS  
 
15.1 Primary Outcome Analyses  
 
The primary endpoint for each arm of the phase II portion of this trial is the 
proportion of confirmed tumor responses.  A confirmed response is defined to be 
a CR, VGPR, or PR noted as the objective status.  Response will be evaluated 
using up to 12 cycle s of treatment.  All participants  meeting the eligibility criteria 
who have signed a consent form and have begun treatment will be evaluable for 
response.  
  
15.2 Secondary Outcome Analyses  
 
Survival time is defined as the time from registration to death due to  any cause.  
The distribution of survival time will be estimated using the method of Kaplan -
Meier for the participants  included in evaluating the decision criteria.  
   
 
Amendment 4 12/04/15   Page 52 of 60 
 Progression -free survival time is defined as the time from registration to disease 
progr ession , clinical relapse,  or death due to any ca use.  The distribution of 
progression -free survival will be estimated using the method of Kaplan -Meier.   
 
Duration of overall response is defined for all participants  who have achieved a 
confirmed response as the date at which the participant’s  objective status is first 
noted to be a CR, sCR, nCR, VGPR, or PR to the earliest date progression or 
clinical relapse is documented.  The distribution of duration of response will be 
estimated using the method of Kaplan -Meier.  
 
 
16.0 STATISTICAL ANALYSIS  
 
In the Phase 2 portion, the largest success proportion where the proposed treatment 
regimen would be considered ineffectiv e in this population is 20%, and the smallest 
success proportion that would warrant further treatment is 40%.  The following one -stage 
design uses 24 participants  to test the null hypothesis that the true success proportion is at 
most 20%.   
 
Enter 24 participants  into the phase 2 portion of the study.  If 7 or fewer successes are 
observed, we will consider this treatment ineffective in this participant  population .  If 8 or 
more successes are observed, we may recommend further testing of the regimen in 
subsequent studies in this population.  
 
Power and Significance Level:  Assuming that the number of successes is binomially 
distributed, the significance level is 0.10, i.e. there is a 10% chance of finding the drug to 
be effective when it truly is not.  The pr obability of declaring that this regimen warrants 
further study ( i.e. statistical power) under various success proportions , and the probability 
of stopping after the first stage can be tabulated as a function of the true success 
proportion.  
 
 
Amendment 4 12/04/15   Page 53 of 60 
 17.0 REFERENCES  
 
1. Jemal, A., et al., Cancer statistics, 2006.  CA Cancer J Clin, 2006. 56(2): p. 
106-30. 
2. Marmont, F., et al., Lack of correlation between objective response and death 
rate in multiple myeloma patients treated with oral melphalan and prednisone.  
Ann Oncol, 1991. 2(3): p. 191 -5. 
3. Cooper, M.R., et al., Single, sequential, and multiple alkylating agent therapy 
for multiple myeloma: a CALGB Study.  J Clin Oncol, 1986. 4(9): p. 1331 -9. 
4. Pavlovsky, S., et al., An update of t wo randomized trials in previously untreated 
multiple myeloma comparing melphalan and prednisone versus three - and five -
drug combinations: an Argentine Group for the Treatment of Acute Leukemia 
Study.  J Clin Oncol, 1988. 6(5): p. 769 -75. 
5. Osterborg, A., et al., Alternating combination chemotherapy (VMCP/VBAP) is 
not superior to melphalan/prednisone in the treatment of multiple myeloma 
patients stage III --a randomized study from MGCS.  Eur J Haematol, 1989. 
43(1): p. 54 -62. 
6. Boccadoro, M., et al., Multipl e myeloma: VMCP/VBAP alternating 
combination chemotherapy is not superior to melphalan and prednisone even in 
high -risk patients.  J Clin Oncol, 1991. 9(3): p. 444 -8. 
7. Blade, J., et al., Alternating combination VCMP/VBAP chemotherapy versus 
melphalan/prednisone in the treatment of multiple myeloma: a randomized 
multicentric study of 487 patients.  J Clin Oncol, 1993. 11(6): p. 1165 -71. 
8. Gregory, W.M., M.A. Richards, and J.S. Malpas, Combination chemotherapy 
versus melphalan and prednisolone in the treatment of multiple myeloma: an 
overview of published trials.  J Clin Oncol, 1992. 10(2): p. 334 -42. 
9. Barlogie, B., L. Smith, and R. Alexanian, Effective treatment of advanced 
multiple myeloma refractory to alkylating agents.  N Engl J Med, 1984. 310(21): 
p. 1353 -6. 
10. Salmon, S.E., R.K. Shadduck, and A. Schilling, Intermittent high -dose 
prednisone (NSC -10023) therapy for multiple myeloma.  Cancer Chemother 
Rep, 1967. 51(3): p. 179 -87. 
11. Mandelli, F., et al., Maintenance treatment with recombinan t interferon alfa -
2b in patients with multiple myeloma responding to conventional induction 
chemotherapy.  N Engl J Med, 1990. 322(20): p. 1430 -4. 
12. Browman, G.P., et al., Randomized trial of interferon maintenance in multiple 
myeloma: a study of the Nati onal Cancer Institute of Canada Clinical Trials 
Group.  J Clin Oncol, 1995. 13(9): p. 2354 -60. 
13. Salmon, S.E., et al., Interferon versus interferon plus prednisone remission 
maintenance therapy for multiple myeloma: a Southwest Oncology Group 
Study.  J Cli n Oncol, 1998. 16(3): p. 890 -6. 
14. Attal, M., et al., A prospective, randomized trial of autologous bone marrow 
transplantation and chemotherapy in multiple myeloma. Intergroupe Francais 
du Myelome.  N Engl J Med, 1996. 335(2): p. 91 -7. 
15. Adams, J., et a l., Proteasome inhibitors: a novel class of potent and effective 
antitumor agents.  Cancer Res, 1999. 59(11): p. 2615 -22. 
 
Amendment 4 12/04/15   Page 54 of 60 
 16. Teicher, B.A., et al., The proteasome inhibitor PS -341 in cancer therapy.  Clin 
Cancer Res, 1999. 5(9): p. 2638 -45. 
17. Curran, M.P.  and K. McKeage, Bortezomib: a review of its use in patients with 
multiple myeloma.  Drugs, 2009. 69(7): p. 859 -88. 
18. Ludwig, H., et al., Proteasome inhibition and its clinical prospects in the 
treatment of hematologic and solid malignancies.  Cancer, 2005 . 104(9): p. 
1794 -807. 
19. Demo, S.D., et al., Antitumor activity of PR -171, a novel irreversible inhibitor 
of the proteasome.  Cancer Res, 2007. 67(13): p. 6383 -91. 
20. Kuhn, D.J., et al., Potent activity of carfilzomib, a novel, irreversible inhibitor 
of the ubiquitin -proteasome pathway, against preclinical models of multiple 
myeloma.  Blood, 2007. 110(9): p. 3281 -90. 
21. Alsina M, T.S., Vallone M, Molineaux C, Kunkel L and Goy A, Phase 1 
Single Agent Activity of Twice Weekly Consecutive Day Dosing of the 
Proteasome Inhibitor Carfilzomib (PR -171) in Hematologic Malignancies.  
Blood, 2007. 110: p. 411.  
22. O'Connor, O.A., et al., A phase 1 dose escalation study of the safety and 
pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR -171) in 
patient s with hematologic malignancies.  Clin Cancer Res, 2009. 15(22): p. 
7085 -91. 
23. Jagannath S, V.R., Stewart K, Somlo G, Jakubowiak A, Trudel S, Schwartz 
R, Siegel D, Kunkel L, The Multiple Myeloma Research Consortium 
(MMRC), Final results of PX-171-003-A0, part 1 of an open -label, single -arm, 
phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and 
refractory multiple myeloma (MM).  J Clin Oncol, 2009. 27(15s): p. (suppl; 
abstr 8504).  
24. Vij R, W.M., Orlowski R, Stewart AK, Jaga nnath S, Kukreti V. Le,MHL, 
Kunkel L, Siegel D. Multiple Myeloma Research Consortium (MMRC), PX-
171-004, a multicenter phase II study of carfilzomib (CFZ) in patients with 
relapsed myeloma: An efficacy update. .  J Clin Oncol, 2009. 27(15s): p. (suppl; 
abstr 8537).  
25. Harris, L., et al., Liposome -encapsulated doxorubicin compared with 
conventional doxorubicin in a randomized multicenter trial as first -line therapy 
of metastatic breast carcinoma.  Cancer, 2002. 94(1): p. 25 -36. 
26. O'Brien, M.E., et al., Redu ced cardiotoxicity and comparable efficacy in a 
phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus 
conventional doxorubicin for first -line treatment of metastatic breast cancer.  
Ann Oncol, 2004. 15(3): p. 440 -9. 
27. Rifkin, R.M., et al., Pegylated liposomal doxorubicin, vincristine, and 
dexamethasone provide significant reduction in toxicity compared with 
doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed 
multiple myeloma: a Phase III multicenter randomize d trial.  Cancer, 2006. 
106(4): p. 848 -58. 
28. Dimopoulos, M.A., et al., Prospective randomized comparison of vincristine, 
doxorubicin and dexamethasone (VAD) administered as intravenous bolus 
 
Amendment 4 12/04/15   Page 55 of 60 
 injection and VAD with liposomal doxorubicin as first -line treat ment in 
multiple myeloma.  Ann Oncol, 2003. 14(7): p. 1039 -44. 
29. Di Bella, N.J., et al., Pegylated liposomal doxorubicin as single -agent treatment 
of low -grade non -Hodgkin's lymphoma: a phase II multicenter study.  Clin 
Lymphoma, 2003. 3(4): p. 235 -40. 
30. Tsavaris, N., et al., Pegylated liposomal doxorubicin in the CHOP regimen for 
older patients with aggressive (stages III/IV) non -Hodgkin's lymphoma.  
Anticancer Res, 2002. 22(3): p. 1845 -8. 
31. Aviles, A., et al., Pegylated liposomal doxorubicin in combina tion 
chemotherapy in the treatment of previously untreated aggressive diffuse large -
B-cell lymphoma.  Med Oncol, 2002. 19(1): p. 55 -8. 
32. Voorhees, P.M., et al., The proteasome as a target for cancer therapy.  Clin 
Cancer Res, 2003. 9(17): p. 6316 -25. 
33. Orlowski, R.Z. and A.S. Baldwin, Jr., NF-kappaB as a therapeutic target in 
cancer.  Trends Mol Med, 2002. 8(8): p. 385 -9. 
34. Orlowski, R.Z. and E.C. Dees, The role of the ubiquitination -proteasome 
pathway in breast cancer: applying drugs that affect the ubi quitin -proteasome 
pathway to the therapy of breast cancer.  Breast Cancer Res, 2003. 5(1): p. 1 -7. 
35. Mitsiades, N., et al., The proteasome inhibitor PS -341 potentiates sensitivity of 
multiple myeloma cells to conventional chemotherapeutic agents: therapeutic 
applications.  Blood, 2003. 101(6): p. 2377 -80. 
36. Nagore, E., A. Insa, and O. Sanmartin, Antineoplastic therapy -induced palmar 
plantar erythrodysesthesia ('hand -foot') syndrome. Incidence, recognition and 
management.  Am J Clin Dermatol, 2000. 1(4): p. 225 -34. 
37. Fabian, C.J., et al., Pyridoxine therapy for palmar -plantar erythrodysesthesia 
associated with continuous 5 -fluorouracil infusion.  Invest New Drugs, 1990. 
8(1): p. 57 -63. 
38. Lopez, A.M., et al., Topical DMSO treatment for pegylated li posomal 
doxorubicin -induced palmar -plantar erythrodysesthesia.  Cancer Chemother 
Pharmacol, 1999. 44(4): p. 303 -6. 
39. Jortner, B.S., Mechanisms of toxic injury in the peripheral nervous system: 
neuropathologic considerations.  Toxicol Pathol, 2000. 28(1): p . 54-69. 
40.  Food and Drug Administration. (July 20, 2012). Approved Drugs - 
Carfilzomib. Food and Drug Administration. Retrieved August, 8, 2012, 
from http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/  
ucm312945.htm   
41. Food and Drug Administration. (February 21, 2012).FDA acts to bolster 
supply of critically needed cancer drugs. Food and Drug Administration. 
Retrieved August, 8, 2012, from http://www.fda.gov/NewsEvents/Newsroom/  
PressAnnouncements/ucm292658.htm  
42. Jakub owiak, A.J. , Phase II Trial of Combination Therapy With Bortezomib, 
Pegylated Liposomal Doxorubicin, and Dexamethasone in Patients With Newly 
Diagnosed Myeloma.  Journal of Clinical Oncology, 2009. 27 (30): p 5015 -
5022.  
  
 
Amendment 4 12/04/15   Page 56 of 60 
 APPENDIX A: ECOG Performance St atus Scale  
 
 
Grade  
  
Description  
0 Normal activity.  Fully active, able to carry on all pre -disease 
performance without restriction.  
1 Symptoms, but ambulatory.  Restricted in physically strenuous 
activity, but ambulatory and able to carry out work of a light or 
sedentary nature (e.g., light housework, office work).  
2 In bed <50% of the time.  Ambulatory and capable of all self -care, but 
unable to carry out any work activities.  Up and about more than 50% 
of waking hours.  
3  
In bed >50% of the time.  Capable of only limited self -care, confined 
to bed or chair more than 50% of waking hours.  
 
4 100% bedridden.  Completely disabled.  Cannot carry on any self -care.  
Totally confined to bed or chair.  
5  
Dead.  
 
  
 
Amendment 4 12/04/15   Page 57 of 60 
  
APPENDIX B :  Karnofsky Performance Status  Scale  
 
DEFINITIONS   RATING (%)   CRITERIA  
Able to carry on normal activity and to work; 
no special care needed.    100   Normal no complaints; no evidence 
of disease.  
90 Able to carry on normal activity; 
minor signs or symptoms of 
disease.  
80 Normal activity with effort; some 
signs or symptoms of disease.  
Unable to work; able to live at home and care 
for most personal needs; varying amount of 
assistance needed.  70 Cares for self; unable to carry on 
normal activity or to do active 
work.  
60 Requires occasional assistance, but 
is able to care for most of his 
personal needs.  
50 Requires considerable assistance 
and frequent medical care.  
Unable to care for self; requires equivalent of 
institutional or hospital care; disease may be 
progressing rapidly.  40 Disabled; requires special care and 
assistance.  
30 Severely disabled; hospital 
admission is indicated although 
death not imminent.  
20 Very sick; hospital admission 
necessary; active supportive 
treatment necessary.  
10 Moribund; fatal processes 
progressing rapidly.  
0 Dead  
  
 
Amendment 4 12/04/15   Page 58 of 60 
  
APPENDIX C : Cockcroft -Gault Formula  
 
 
 
  

 
Amendment 4 12/04/15   Page 59 of 60 
 APPENDIX D : NCI Common Terminology  Criteria for Adverse Events  Version 4.0  
 
Adverse Events will be scored using the NCI Common Terminology  Criteria for Adverse 
Events (CTCAE) Version 4.0.  
 
A copy of the NCI CTCAE Version 4.0 can be downloaded from:  
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 -06-14_QuickReference_5x7.pdf  
  
  
 
Amendment 4 12/04/15   Page 60 of 60 
  
APPENDIX E : Medwatch 3500  
 
Reportable adverse events and pregnancies will be re ported to the appropriate on a 
Medwat ch 3500 form. The most recent Medw atch 3500 Form  can be retrieved from  
http://www.fda.gov/medwatch/safety/FDA -3500_fillable.pdf   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 